:: CLDF ::

Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response

Clin Gastroenterol Hepatol. 2022 Feb;20(2):438-446.doi: 10.1016/j.cgh.2021.01.026. Epub 2021 Jan 22.

Zobair M Younossi¹, Andrei Racila², Andrew Muir³, Marc Bourliere⁴, Alessandra Mangia⁵, Rafael Esteban⁶, Stefan Zeuzem⁷, Massimo Colombo⁸, Michael Manns⁹, George V Papatheodoridis¹⁰, Maria Buti⁶, Anand Chokkalingam¹¹, Anuj Gaggar¹¹, Fatema Nader¹², Issah Younossi¹², Linda Henry¹², Maria Stepanova¹²

Laboratory-based testing for hepatitis C infection using dried blood spot samples: A systematic review and meta-analysis of diagnostic accuracy

Rev Med Virol. 2021 Dec 26;e2320. doi: 10.1002/rmv.2320. Online ahead of print.

Paul G Carty¹², Michael McCarthy², Sinéad M O'Neill², Cillian F De Gascun³, Patricia Harrington², Michelle O'Neill², Susan M Smith⁴, Conor Teljeur², Mairin Ryan²⁵

The management of infants, children, and youth at risk for hepatitis C virus infection

Paediatr Child Health. 2021 Nov 11;26(7):440-441. doi: 10.1093/pch/pxab073.eCollection 2021 Nov.

Ari Bitnun¹

Hepatitis C: Current State of Treatment in Children

Pediatr Clin North Am. 2021 Dec;68(6):1321-1331. doi: 10.1016/j.pcl.2021.07.008.

Sanu R Yadav¹, Deborah A Goldman¹, Karen F Murray²

The curing regimens of HCV: A SWOT analysis

Antivir Ther. Feb-Apr 2022;27(1-2):13596535211072672. doi: 10.1177/13596535211072672.

Markus Cornberg¹²³, Michael P Manns⁴

Prevalence of hepatitis C in sexual assault survivors presenting to a SANE clinic: A descriptive analysis

Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13675. Online ahead of print.

Erin Ward¹, Nicholas Carlisle², Ebony Williams², Sonya L Heath³, Kellie Meloun⁴, Lauren A Walter⁵

Community pharmacist engagement in HIV and HCV prevention: Current practices and potential for service uptake

Explor Res Clin Soc Pharm. 2021 Oct 28;4:10008 doi: 10.1016/j.rcsop.2021.100088.eCollection 2021 Dec.

KariLynn Dowling-McClay¹, Stephanie M Mathis², Nicholas Hagemeier¹

Nurse practitioners as primary care site champions for the screening and treatment of hepatitis C virus

J Am Assoc Nurse Pract. 2022 Jan 21;34(4):688-695. doi: 10.1097/JXX.0000000000000689.

Cheryl H Dale¹, Elizabeth Smith¹², Mia J Biondi¹³

HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis

Hepatology. 2022 Jan 14. doi: 10.1002/hep.32341. Online ahead of print.

Ian Lockart¹², Malcolm G H Yeo¹, Behzad Hajarizadeh³, Gregory J Dore²³, Mark Danta¹²

10.

Global incidence and mortality of hepatitis B and hepatitis C acute infections, cirrhosis and hepatocellular carcinoma from 2010 to 2019

J Viral Hepat. 2022 May;29(5):352-365. doi: 10.1111/jvh.13663. Epub 2022 Mar 15.

Nicolette Veracruz¹, Robert G Gish², Ramsey Cheung³⁴, Amit S Chitnis⁵, Robert J Wong³⁴

11.

Epidemiology of Hepatitis C virus infection among incarcerated populations in North Dakota

PLoS One. 2022 Mar 29;17(3):e0266047. doi: 10.1371/journal.pone.0266047. eCollection 2022.

Liton Chandra Deb¹², Hannah Hove¹³, Tracy K Miller⁴, Kodi Pinks⁴, Grace Njau⁴, John J Hagan⁵, Rick J Jansen¹⁶⁷⁸

12.

Micro-elimination of hepatitis C in people who use injectable drugs along the USA-Mexico border: a modelling study

Lancet Glob Health. 2022 Mar;10 Suppl 1:S6. doi: 10.1016/S2214-109X(22)00135-8.

Lara K Marquez¹, Clara Fleiz², Carlos Magis-Rodriguez³, Natasha K Martin⁴

13.

Individualized Provider Feedback Increased HIV and HCV Screening and Identification in a New York City Emergency Department

AIDS Patient Care STDS. 2022 Mar;36(3):106-114. doi: 10.1089/apc.2021.0225.

Jason Zucker¹, Lawrence Purpura¹², Fereshteh Sani³, Simian Huang¹, Aaron Schluger⁴, Kenneth Ruperto⁵, Jacek Slowkowski⁵, Susan Olender¹, Matt Scherer¹, Delivette Castor¹, Peter Gordon¹

14.

Feasibility of hepatitis C virus testing and linkage in community supervision offices: Great potential but persistent challenges

Int J Drug Policy. 2022 Mar 31;103:103668. doi: 10.1016/j.drugpo.2022.103668.Online ahead of print.

Brendan P Jacka¹, Laurie B Bazerman², Collin Dickerson³, Marc Moody⁴, Johanna Martin², Emily Patry², Treniece Cady², Hacheming Compere², Matthew Boudreau², Curt G Beckwith⁵

15.

A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study

Hepatology. 2021 Dec;74(6):2952-2964.doi: 10.1002/hep.32053.Epub 2021 Aug 26.

Mark S Sulkowski¹, Juhi S Moon¹, Kenneth E Sherman², Giuseppe Morelli³, Jama M Darling⁴, Andrew J Muir⁵, Mandana Khalili⁶, Dawn A Fishbein⁷, Federico Hinestrosa⁸, Mitchell L Shiffman⁹, Adrian Di Bisceglie¹⁰, K Rajender Reddy¹¹, Brian Pearlman¹², Anna S Lok¹³, Michael W Fried⁴, Paul W Stewart¹⁴, Joy Peter³, Summer Wadsworth¹⁵, Scott Kixmiller¹⁶, Anquenette Sloan¹⁷, Monika Vainorius⁴, Patrick M Horne³, Larry Michael¹⁴, Meichen Dong¹⁴, Donna M Evon⁴, Jodi B Segal¹⁸, David R Nelson³, PRIORITIZE Study Team

16.

Patient-centered HCV care via telemedicine for individuals on medication for opioid use disorder: Telemedicine for Evaluation, Adherence and Medication for Hepatitis C (TEAM-C)

Contemp Clin Trials. 2022 Jan;112:106632.doi: 10.1016/j.cct.2021.106632. Epub 2021 Nov 20.

Andrew H Talal¹, Marianthi Markatou², Elisavet M Sofikitou³, Lawrence S Brown⁴, Ponni Perumalswami⁵, Amreen Dinani⁶, Jonathan N Tobin⁷

17.

Diagnosis of hepatitis C infection and cascade of care in the active component, U.S. Armed Forces, 2020

MSMR. 2022 Feb 1;29(2):2-7.

Mitchell Legg, Nicholas Seliga, Heather Mahaney, Todd Gleeson, James Mancuso

18.

Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension

Infect Dis Ther. 2022 Apr;11(2):913-924. doi: 10.1007/s40121-022-00599-8. Epub 2022 Feb 17.

Robert S Brown Jr¹, Michelle A Collins², Simone I Strasser³, Amanda Emmett², Andrew S Topp², Margaret Burroughs², Rosa Ferreira², Jordan J Feld⁴

19.

Hepatitis C Virus Direct-Acting Antiviral Treatment Adherence Patterns and Sustained Viral Response Among People Who Inject Drugs Treated in Opioid Agonist Therapy Programs

Clin Infect Dis. 2021 Dec 6;73(11):2093-2100.doi: 10.1093/cid/ciab334.

Moonseong Heo¹, Irene Pericot-Valverde², Lior Rennert¹, Matthew J Akiyama³, Brianna L Norton³, Mirinda Gormley¹, Linda Agyemang³, Julia H Arnsten³, Alain H Litwin²⁴⁵

20.

Formal Hepatitis C Education Increases Willingness to Receive Therapy in an On-site Shelter-Based HCV Model of Care in Persons Experiencing Homelessness

Open Forum Infect Dis. 2022 Mar 1;9(4):ofac103. doi: 10.1093/ofid/ofac103.eCollection 2022 Apr.

Diana Partida¹, Jesse Powell², Margaret Ricco², Jessica Naugle³, Catherine Magee⁴, Barry Zevin³, Carmen L Masson⁵, J Konadu Fokuo⁵, Daniel Gonzalez⁶⁷, Mandana Khalili⁶⁷

21.

Emergency department versus community screening on hepatitis C follow-up care

Am J Emerg Med. 2022 Mar 24;56:151-157. doi: 10.1016/j.ajem.2022.03.041.Online ahead of print.

Austin T Jones¹, Lisa Moreno-Walton², Torrence Tran³, Christopher Briones³, Kanayo Okeke-Eweni², Rachael Stevens⁴, Kacie Isaacson⁵, Hua He⁶, Patricia J Kissinger⁶

22.

Implementation of HCV screening in the 1969-1989 birth-cohort undergoing COVID-19 vaccination

Liver Int. 2022 Feb 27. doi: 10.1111/liv.15216. Online ahead of print.

Roberta D'Ambrosio¹, Giuliano Rizzardini², Massimo Puoti³, Stefano Fagiuoli⁴, Maria Paola Anolli¹, Claudia Gabiati⁵, Federico D'Amico³, Luisa Pasulo⁴, Umberto Restelli⁶⁷, Massimo Colombo⁸, Pietro Lampertico¹⁹

23.

Long-term Follow-up of Hepatitis C Patients Who Achieved Sustained Virologic Response in the Pragmatic PRIORITIZE Study

Clin Gastroenterol Hepatol. 2022 Feb 17;S1542-3565(22)00179-3.doi: 10.1016/j.cgh.2022.01.059. Online ahead of print.

Anna S Lok¹, Juhi Moon², Kenneth E Sherman³, Mandana Khalili⁴, Dawn Fishbein⁵, K Rajender Reddy⁶, PRIORITIZE Study Team

24.

Outcomes of Adult Liver Retransplantation: A Canadian National Database Analysis

Can J Gastroenterol Hepatol. 2022 Mar 22;2022:9932631. doi: 10.1155/2022/9932631.eCollection 2022.

Peter D Yoon^1 2, Madhukar S Patel^1 3, Carla F Murillo Perez⁴, Tommy Ivanics^1 5 6, Marco P A W Claasen^1 7, Hala Muaddi¹, David Wallace^1 8 9, Bettina Hansen^4 10, Gonzalo Sapisochin¹

25.

Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up study

Liver Int. 2022 Feb 26. doi: 10.1111/liv.15211. Online ahead of print.

Fred Poordad¹, Franco Felizarta², Betty B Yao³, J Scott Overcash⁴, Tarek Hassanein⁵, Kosh Agarwal⁶, Edward Gane⁷, David Shaw⁸, Michael Waters⁴, Preethi Krishnan³, Andrew Topp³, Margaret Burroughs³, Frederik Nevens⁹

26.

A global systematic review of hepatitis C elimination efforts through micro-elimination

Semin Liver Dis. 2022 Feb 21. doi: 10.1055/a-1777-6112. Online ahead of print.

Jeffrey V Lazarus^1 2, Camila A Picchio², Christopher Byrne³, Javier Crespo⁴, Massimo Colombo⁵, Graham Cooke⁶, Gregory J Dore⁷, Jason Grebely⁷, John W Ward⁸, John Dillon^9 3

27.

Prevalence and outcomes of chronic liver disease in patients receiving dialysis: systematic review and meta-analysis

Clin Kidney J. 2021 Nov 18;15(4):747-757. doi: 10.1093/ckj/sfab230. eCollection 2022 Apr.

Oscar Swift¹, Shivani Sharma², Sivaramakrishnan Ramanarayanan¹, Hamza Umar³, Keith R Laws², Enric Vilar¹, Ken Farrington¹

28.

Hepatitis C: Standard of Treatment and What to Do for Global Elimination

Viruses. 2022 Feb 28;14(3):505. doi: 10.3390/v14030505.

Lorenza Di Marco^1 2, Claudia La Mantia³, Vito Di Marco³

29.

Removal of medicaid restrictions were associated with increased hepatitis C virus treatment rates, but disparities persist

J Viral Hepat. 2022 Mar 7. doi: 10.1111/jvh.13661. Online ahead of print.

Lauren D Nephew^1 2, Yumin Wang³, Kawthar Mohamed⁴, Deborah Nichols⁵, Susan M Rawl^2 6, Eric Orman¹, Archita P Desai¹, Kavish R Patidar¹, Marwan Ghabril¹, Naga Chalasani¹, Monica L Kasting^2 7

30.

Treatment-Resistant Hepatitis C Viral Infection: A Case Report and Literature Review

Case Reports Hepato. 2022 Mar 11;2022:3556780.doi: 10.1155/2022/3556780. eCollection 2022.

Victoria Green¹, Marina Roytman²

31.

Knowledge of hepatitis C and awareness of reinfection risk among people who successfully completed direct acting antiviral therapy

PLoS One. 2022 Mar 23;17(3):e0265811. doi: 10.1371/journal.pone.0265811. eCollection 2022.

Kiana Yazdani¹, Katerina Dolguikh¹, Wendy Zhang¹, Sara Shayegi-Nik^1 2, Jessica Ly¹, Shaughna Cooper¹, Jason Trigg¹, Sophia Bartlett^3 4, Rolando Barrios^1 3, Julio S G Montaner¹, Kate Salters^1 5

32.

The Importance of Prisons in Achieving Hepatitis C Elimination: Insights from the Australian Experience

Viruses. 2022 Feb 28;14(3):497. doi: 10.3390/v14030497.

Rebecca J Winter^1 2 3, Jacinta A Holmes^2 4, Timothy J Papaluca^2 4, Alexander J Thompson^2 4

33.

Sustained impact of the COVID-2019 pandemic on HCV treatment initiations in the United States

Clin Infect Dis. 2022 Mar 2;ciac175. doi: 10.1093/cid/ciac175. Online ahead of print.

Martin Hoenigl^1 2, Daniela Abramovitz¹, Ricardo E Flores Ortega¹, Natasha K Martin^1 3, Nancy Reau⁴

34.

The impact of point-of-care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study

J Viral Hepat. 2022 Mar 11. doi: 10.1111/jvh.13664. Online ahead of print.

Jessica Howell^1 2 3 4, Michael W Traeger^1 2, Bridget Williams¹, Chloe Layton⁵, Joseph S Doyle^1 6, Ned Latham^1 7, Bridget Draper^1 2, Frances Bramwell⁵, Dean Membrey⁵, Maggie Mcpherson⁸, Janine Roney⁹, Mark Stoové¹, Alexander J Thompson^3 4, Margaret E Hellard^1 2 6 10, Alisa Pedrana^1 2

35.

Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis

Lancet Gastroenterol Hepatol. 2022 Mar 15;S2468-1253(21)00471-4.doi: 10.1016/S2468-1253(21)00471-4. Online ahead of print.

Evan B Cunningham¹, Alice Wheeler², Behzad Hajarizadeh², Clare E French³, Rachel Roche⁴, Alison D Marshall⁵, Guillaume Fontaine⁶, Anna Conway⁵, Braulio M Valencia², Sahar Bajis², Justin Presseau⁷, John W Ward⁸, Louisa Degenhardt⁹, Gregory J Dore², Matthew Hickman¹⁰, Peter Vickerman¹⁰, Jason Grebely²

36.

Detection of Recurrent Hepatitis C Viremia Using Surveillance Data, New York City

J Public Health Manag Pract. 2022 Mar-Apr 01;28(2):126-129.doi: 10.1097/PHH.0000000000001150.

Kevin Guerra¹, Angelica Bocour, Miranda S Moore, Ann Winters

37.

Low Utilization of Direct-Acting Antiviral Agents in a Large National Cohort of HIV and HCV Coinfected Medicare Patients in the United States: Implications for HCV Elimination

J Public Health Manag Pract. 2022 Mar-Apr 01;28(2):130-134.doi: 10.1097/PHH.0000000000001147.

Ping Du¹, Jeah Jung, Yamini Kalidindi, Kevin Farrow, Thomas Riley 3rd, Cynthia Whitener

38.

Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral based treatment regimens: evidence from a global dataset

J Viral Hepat. 2022 Mar 12. doi: 10.1111/jvh.13672. Online ahead of print.

Jake R Morgan¹, Elizabeth Marsh², Alexandra Savinkina², Sonjelle Shilton³, Shaun Shadaker⁴, Tengiz Tsertsvadze⁵, George Kamkamidze⁶, Maia Alkhazashvili⁷, Tim Morgan⁸, Pam Belperio⁸, L Backus⁸, Waheed Doss⁹, Gamal Esmat⁹, Mohamed Hassany⁹, Aisha Elsharkawy⁹, Wafaa Elakel⁹, Mai Mehrez⁹, Graham R Foster¹⁰, Kinge Wose¹¹, Kara W Chew¹², Charles S Chasela¹³, Ian M Sanne¹⁴, Yin M Thanung¹⁵, Anne Loarec¹⁶, Khawar Aslam¹⁷, Suna Balkan¹⁸, Philippa J Easterbrook¹⁹, Benjamin P Linas^2 20

39.

The Payer License Agreement, or "Netflix model," for hepatitis C virus therapies enables universal treatment access, lowers costs, and incentivizes innovation and competition

Liver Int. 2022 Mar 15. doi: 10.1111/liv.15245. Online ahead of print.

David W Matthews^1 2, Samantha Coleman³, Homie Razavi³, Jean-Manuel Izaret^1 2

40.

Accessible Hepatitis C Care for People Who Inject Drugs: A Randomized Clinical Trial

JAMA Intern Med. 2022 Mar 14. doi: 10.1001/jamainternmed.2022.0170. Online ahead of print.

Benjamin Eckhardt¹, Pedro Mateu-Gelabert², Yesenia Aponte-Melendez², Chunki Fong², Shashi Kapadia³, Melinda Smith³, Brian R Edlin^4 5, Kristen M Marks³

41.

The Association Between Self-Reported Non-Injection Cocaine Use and Hepatitis C in the United States: An Analysis of the National Health and Nutrition Examination Survey

J Stud Alcohol Drugs. 2022 Mar;83(2):195-201.

Alison E Simmons¹, Ania I Fiedler², David N Fisman¹, Susan J Bondy¹

42.

High-Risk Injection-Related Practices Associated with anti-HCV Positivity among Young Adults Seeking Services in Three Small Cities in Wisconsin

Subst Use Misuse. 2022 Mar 4;1-9. doi: 10.1080/10826084.2022.2026964.Online ahead of print.

Jessica Rogers-Brown¹, Farah Sublett², Lauren Canary¹, David B Rein², Maithili Bhat¹, William W Thompson¹, Claudia Vellozzi¹, Alice Asher¹

43.

Effect of a Default Order vs an Alert in the Electronic Health Record on Hepatitis C Virus Screening Among Hospitalized Patients: A Stepped-Wedge Randomized Clinical Trial

JAMA Netw Open. 2022 Mar 1;5(3):e222427. doi: 10.1001/jamanetworkopen.2022.2427.

Shivan J Mehta¹², Jessie Torgersen¹, Dylan S Small³, Colleen P Mallozzi⁴⁵, John D McGreevey 3rd¹⁴⁵, Charles A L Rareshide¹⁶, Chalanda N Evans¹⁶, Mika Epps⁴, David Stabile⁴, Christopher K Snider^2 6, Mitesh S Patel^{1 3 6 7 8}

44.

Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans

Dig Dis Sci. 2022 Mar 9. doi: 10.1007/s10620-022-07454-3. Online ahead of print.

Elliot B Tapper¹, Zhe Zhao², Nik Mazumder², Neehar D Parikh²

45.

Real-world monitoring progress towards the elimination of hepatitis C virus in Australia using sentinel surveillance of primary care clinics; an ecological study of hepatitis C virus antibody tests from 2009 to 2019

Epidemiol Infect. 2021 Dec 6;150:e7. doi: 10.1017/S0950268821002624.

Anna Lee Wilkinson^1 2, Alisa Pedrana^1 2, Michael W Traeger^1 2, Jason Asselin¹, Carol El-Hayek¹, Long Nguyen¹, Victoria Polkinghorne¹, Joseph S Doyle^1 3, Alexander J Thompson^4 5, Jessica Howell^1 2 4 5, Nick Scott^1 2, Wayne Dimech⁶, Rebecca Guy⁷, Margaret Hellard^1 2 3 8, Mark Stoové^1 2, EC Victoria Partnership and the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of blood-borne viruses AND sexually transmissible infections (ACCESS)

46.

Does Preoperative Antiviral Treatment for Hepatitis C Decrease Risk of Complications After Total Hip Arthroplasty? A Matched Cohort Study

Arthroplasty. 2022 Mar 3;S0883-5403(22)00253-4. doi: 10.1016/j.arth.2022.02.102.Online ahead of print.

Austin J Ross¹, Bailey J Ross¹, Olivia C Lee², Hunter W Hood¹, Fernando L Sanchez¹, William F Sherman³

47.

Statewide Assessment of the Hepatitis C Virus Care Cascade for Incarcerated Persons in Vermont

Public Health Rep. 2022 Mar 9;333549221077070. doi: 10.1177/00333549221077070.Online ahead of print.

Andrew J Hale^1 2, Shivani Mathur², Jean Dejace^1 2, Steven D Lidofsky^1 2

48.

In the Era of Direct-Acting Antivirals, Liver Transplant Delisting Due to Clinical Improvement for Hepatitis C Remains Infrequent

Clin Gastroenterol Hepatol. 2021 Nov;19(11):2389-2397.e2. doi: 10.1016/j.cgh.2020.09.033.Epub 2020 Sep 21.

Therese Bittermann¹, K Rajender Reddy²

49.

Microelimination of Hepatitis C Among People With Human Immunodeficiency Virus Coinfection: Declining Incidence and Prevalence Accompanying a Multicenter Treatment Scale-up Trial

Clin Infect Dis. 2021 Oct 5;73(7):e2164-e2172. doi: 10.1093/cid/ciaa1500.

Joseph S Doyle^1 2, Daniela K van Santen^1 3, David Iser^2 4, Joe Sasadeusz^2 5, Mark O'Reilly⁶, Brendan Harney^1 2, Michael W Traeger^1 3, Janine Roney², Julia C Cutts¹, Anna L Bowring¹, Rebecca Winter^1 4, Nick Medland⁷, Christopher K Fairley⁷, Richard Moore⁸, B K Tee⁹, Jason Asselin¹, Carol El-Hayek¹, Jennifer F Hoy², Gail V Matthews¹⁰, Maria Prins^11 12, Mark A Stoové^1 3, Margaret E Hellard^1 2 3 13

50.

Hepatitis C Epidemiology in a Large Urban Jail: A Changing Demographic

Public Health Rep. 2022 Mar 3;333549221076546. doi: 10.1177/00333549221076546.Online ahead of print.

Emily Hoff¹, Andrea Warden², Ruby Taylor², Ank E Nijhawan^1 2

51.

Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairment

Aliment Pharmacol Ther. 2022 Mar 2. doi: 10.1111/apt.16830. Online ahead of print.

Mark Sulkowski¹, Laura E Telep², Massimo Colombo³, Francois Durand⁴, K Rajender Reddy⁵, Eric Lawitz⁶, Marc Bourlière^7 8, Nelson Cheinquer², Stacey Scherbakovsky², Liyun Ni², Lindsey Force², Heribert Ramroth², Anuj Gaggar², Anand P Chokkalingam², Meghan E Sise⁹

52.

Outcomes of community-based hepatitis C treatment by general practitioners and nurses in Australia through remote specialist consultation

Intern Med J. 2021 Nov;51(11):1927-1934. doi: 10.1111/imj.15037. Epub 2021 Oct 28.

James Haridy^1 2 3, Guru Iyngkaran^1 2 4, Amanda Nicoll^1 3 5, Kate Muller⁶, Mark Wilson⁷, Alan Wigg⁶, Jeyamani Ramachandran⁶, Renjy Nelson^8 9, Stephen Bloom^3 5, Joseph Sasadeusz¹⁰, Sally Watkinson¹⁰, Anton Colman¹¹, Rosalie Altus⁶, Emma Tilley⁶, Jeffrey Stewart^6 9, Geoff Hebbard², Danny Liew¹², Edmund Tse^8 11

53.

Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States

Clin Infect Dis. 2021 Nov 2;73(9):e3355-e3357. doi: 10.1093/cid/ciaa362.

Antoine Chaillon¹, Adriane Wynn¹, Tatyana Kushner², Nancy Reau³, Natasha K Martin^1 4

54.

You Can't Have One Without the Other: Innovation and Ethical Dilemmas in Gastroenterology and Hepatology

Clin Gastroenterol Hepatol. 2021 Oct;19(10):2015-2019.doi: 10.1016/j.cgh.2020.05.024. Epub 2020 May 20.

Thomas Couri¹, Andrew Aronsohn²

55.

Educating Primary Care Providers and Associate Care Providers About Hepatitis C Screening of Baby Boomers: a Multi-practice Study

J Cancer Educ. 2022 Feb;37(1):217-223. doi: 10.1007/s13187-020-01805-2.

Bertha E Flores¹, Andrea A Fernandez¹, Chen-Pin Wang^2 3, Raudel Bobadilla³, Ludivina Hernandez³, Mamta K Jain⁴, Barbara J Turner⁵

56.

Nucleic Acid Testing for Diagnosis of Perinatally Acquired Hepatitis C Virus Infection in Early Infancy

Clin Infect Dis. 2021 Nov 2;73(9):e3340-e3346. doi: 10.1093/cid/ciaa949.

Charitha Gowda^1 2, Stephanie Smith¹, Linda Crim¹, Katherine Moyer³, Pablo J Sánchez^1 4 5, Jonathan R Honegger^1 6

57.

Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States

Clin Infect Dis. 2021 Nov 2;73(9):e3355-e3357. doi: 10.1093/cid/ciaa362.

Antoine Chaillon¹, Adriane Wynn¹, Tatyana Kushner², Nancy Reau³, Natasha K Martin^1 4

58.

New hope for hepatitis C virus: Summary of global epidemiologic changes and novel innovations over 20 years

World J Gastroenterol. 2021 Aug 7;27(29):4818-4830.doi: 10.3748/wjg.v27.i29.4818.

Brittany B Dennis¹, Leen Naji², Yasmin Jajarmi¹, Aijaz Ahmed³, Donghee Kim⁴

59.

Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population

Am J Drug Alcohol Abuse. 2022 Jan 25;1-9. doi: 10.1080/00952990.2021.1983821.Online ahead of print.

Jennifer R Kramer^1 2, Amy Puenpatom³, Yumei Cao¹, Xian Yu², Hashem B El-Serag^1 2, Fasiha Kanwal^1 2

60.

Hepatitis C Testing and Linkage to Care Among Adults on Probation in a Large US City

Open Forum Infect Dis. 2021 Dec 16;9(2):ofab636. doi: 10.1093/ofid/ofab636.eCollection 2022 Feb.

Kevin F Kamis¹, David L Wyles², Matthew S Minturn³, Tracy Scott⁴, Dean McEwen¹, Hermione Hurley^1 2 5, Scott J Prendergast⁶, Sarah E Rowan^1 2

61.

Sofosbuvir-Velpatasvir-Voxilaprevir in Adolescents 12 to 17 Years Old With Hepatitis C Virus Infection

Hepatology. 2022 Feb 3. doi: 10.1002/hep.32393. Online ahead of print.

Guiseppe Indolfi¹, Deirdre Kelly², Gabriella Nebbia³, Raffaele Iorio⁴, Anna Mania⁵, Vania Giacomet⁶, Leszek Szenborn⁷, Jiang Shao⁸, Mun Sang Yue⁸, Chia-Hsiang Hsueh⁸, Bandita Parhy⁸, Kathryn Kersey⁸, Alessandra Mangia⁹, Malgorzata Pawlowska¹⁰, Sanjay Bansal¹¹

62.

Mortality among Alaska Native Adults with Confirmed Hepatitis C Virus Infection Compared with the General Population in Alaska, 1995-2016

Can J Gastroenterol Hepatol. 2022 Feb 8;2022:2573545. doi: 10.1155/2022/2573545.eCollection 2022.

Sara S Bressler¹, Dana Bruden¹, Leisha D Nolen¹, Michael G Bruce¹, Lisa Towshend-Bulson², Philip Spradling³, Brian J McMahon^1 2

63.

Hepatitis C Vaccination: Where We Are and Where We Need to Be

Pathogens. 2021 Dec 14;10(12):1619. doi: 10.3390/pathogens10121619.

Vignan Manne¹, John Ryan², Jonathan Wong¹, Gayatri Vengayil¹, Syed Abdul Basit², Robert G Gish³

64.

Ledipasvir-sofosbuvir in Adolescents with Chronic Hepatitis C and Hematological Malignancies Undergoing Chemotherapy

J Pediatr Gastroenterol Nutr. 2022 Feb 10. doi: 10.1097/MPG.0000000000003406.Online ahead of print.

Manal Hamdy El-Sayed¹, Fatma S Elsayed Ebeid, Abdel-Rahman Zekri, Benedetta Massetto, Kathryn Kersey, Fangqiu Zhang, Anuj Gaggar, Walaa Elsayed, Alaa El-Haddad

65.

Lower rates of emergency visits and hospitalizations among chronic hepatitis C patients with sustained virological response to interferon-free direct-acting antiviral therapy (2014-2018)

Clin Infect Dis. 2022 Feb 11;ciac124. doi: 10.1093/cid/ciac124. Online ahead of print.

Stuart C Gordon¹, Eyasu H Teshale², Philip R Spradling², Anne C Moorman², Joseph A Boscarino³, Mark A Schmidt⁴, Yihe G Daida⁵, Loralee B Rupp⁶, Sheri Trudeau⁷, Jiaqi Zhang⁷, Mei Lu⁷, CHeCS Investigators

66.

Comprehensive Comparative Analysis of Standard Validated, Genetic, and Novel Biomarkers to Enhance Prognostic Risk-stratification in Patients with Hepatitis C Cirrhosis

Clin Transl Gastroenterol. 2022 Feb 9. doi: 10.14309/ctg.0000000000000462.Online ahead of print.

Hamish Innes^1 2 3, Alex J Walker⁴, Jennifer Benselin⁵, Jane I Grove⁵, Vincent Pedergnana^6 7, Shang-Kuan Lin⁷, John McLauchlan⁸, Sharon J Hutchinson^1 3, Eleanor Barnes⁷, William L Irving⁵, Indra Neil Guha⁵, HCV Research UK; & STOP-HCV Consortia; HCV Research UK; & STOP-HCV Consortia

67.

Hepatitis C virus micro-elimination within a clinic for people with HIV: challenges in the home stretch

HIV Med. 2022 Feb 12. doi: 10.1111/hiv.13241. Online ahead of print.

Jaklin Hanna¹, Jihan Sufian¹, Jin S Suh^1 2, Humberto R Jimenez^1 3

68.

Global Utilization Trends of Direct Acting Antivirals (DAAs) during the COVID-19 Pandemic: A Time Series Analysis

Viruses. 2021 Jul 7;13(7):1314. doi: 10.3390/v13071314.

Ahmad Shakeri¹, Natalia Konstantelos^1 2, Cherry Chu¹, Tony Antoniou^3 4, Jordan Feld⁵, Katie J Suda^6 7, Mina Tadrous^1 2

69.

A Digital Case-Finding Algorithm for Diagnosed but Untreated Hepatitis C: A Tool for Increasing Linkage to Treatment and Cure

Hepatology. 2021 Dec;74(6):2974-2987. doi: 10.1002/hep.32086.

Brooke Wyatt¹, Ponni V Perumalswami^1 2 3, Anna Mageras¹, Mark Miller¹, Alyson Harty¹, Ning Ma¹, Chip A Bowman⁴, Francina Collado¹, Jihae Jeon¹, Lismeiry Paulino¹, Amreen Dinani¹, Douglas Dieterich¹, Li Li¹, Maxence Vandromme¹, Andrea D Branch

70.

A hepatitis C elimination model in healthcare for the homeless organization: A novel reflexive laboratory algorithm and equity assessment

Int J Drug Policy. 2021 Oct;96:103359. doi: 10.1016/j.drugpo.2021.103359. Epub 2021 Jul 27.

A Seaman¹, C A King², T Kaser³, A Geduldig³, W Ronan³, R Cook⁴, B Chan⁵, X A Levander⁴, K C Priest⁶, P T Korthuis⁴

71.

Comparison of liver biopsies before and after direct-acting antiviral therapy for hepatitis C and correlation with clinical outcome

Sci Rep. 2021 Jul 15;11(1):14506. doi: 10.1038/s41598-021-93881-7.

Omar A Saldarriaga¹, Bradley Dye², Judy Pham², Timothy G Wanninger², Daniel Millian², Michael Kueht³, Benjamin Freiberg⁴, Netanya Utay⁵, Heather L Stevenson^6 7

72.

Care Facilitation Advances Movement Along the Hepatitis C Care Continuum for Persons With Human Immunodeficiency Virus, Hepatitis C, and Substance Use: A Randomized Clinical Trial (CTN-0064)

Open Forum Infect Dis. 2021 Jun 27;8(8):ofab334. doi: 10.1093/ofid/ofab334.eCollection 2021 Aug.

Lisa R Metsch¹, Daniel J Feaster², Lauren K Gooden¹, Carmen Masson³, David C Perlman⁴, Mamta K Jain⁵, Tim Matheson⁶, C Mindy Nelson², Petra Jacobs⁷, Susan Tross⁸, Louise Haynes⁹, Gregory M Lucas¹⁰, Jonathan A Colasanti¹¹, Allan Rodriguez¹², Mari-Lynn Drainoni¹³, Georgina Osorio⁴, Ank E Nijhawan⁵, Jeffrey M Jacobson¹⁴, Meg Sullivan¹³, David Metzger¹⁵, Pamela Vergara-Rodriguez¹⁶, Ronald Lubelchek¹⁷, Rui Duan², Jacob N Batycki², Abigail G Matthews¹⁸, Felipe Munoz¹⁸, Eve Jelstrom¹⁹, Raul Mandler²⁰, Carlos Del Rio¹¹

73.

Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial

Viruses. 2021 Jul 13;13(7):1351. doi: 10.3390/v13071351.

Christopher C Phelps¹, Christopher M Walker^1 2, Jonathan R Honegger^1 2

74.

Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination

J Prev Med Public Health. 2021 Jul;54(4):251-258. doi: 10.3961/jpmph.21.151. Epub 2021 Jun 24.

Nathalie Brunner¹, Philip Bruggmann^1 2

75.

Hepatitis C Treatment Among Commercially or Medicaid-Insured Individuals, 2014-2018

Am J Prev Med. 2021 Nov;61(5):716-723. doi: 10.1016/j.amepre.2021.05.017. Epub 2021 Aug 3.

Aaron M Harris¹, Mohammed A Khan², Ademola Osinubi², Noele P Nelson², William W Thompson²

76.

Five-Year Follow-Up of Cured HCV Patients under Real-World Interferon-Free Therapy

2021 Jul 22;13(15):3694. doi: 10.3390/cancers13153694.

Robert Flisiak¹, Dorota Zarebska-Michaluk², Ewa Janczewska³, Tadeusz Lapinski¹, Magdalena Rogalska¹, Ewa Karpinska⁴, Tomasz Mikula⁵, Beata Bolewska⁶, Jolanta Bialkowska⁷, Katarzyna Flejscher-Stepniewska⁸, Krzysztof Tomasiewicz⁹, Kornelia Karwowska¹⁰, Monika Pazgan-Simon¹¹, Anna Piekarska¹², Hanna Berak¹³, Olga Tronina¹⁴, Aleksander Garlicki¹⁵, Jerzy Jaroszewicz¹⁶

77.

A Systematic Review and Meta-Analysis of Studies Evaluating the Effect of Medication Treatment for Opioid Use Disorder on Infectious Disease Outcomes

Open Forum Infect Dis. 2021 Jun 2;8(8):ofab289. doi: 10.1093/ofid/ofab289.eCollection 2021 Aug.

Katelyn F McNamara¹, Breanne E Biondi², Raúl U Hernández-Ramírez^3 4, Noor Taweh^5 6, Alyssa A Grimshaw⁷, Sandra A Springer^5 4

78.

Reexamining Risk Aversion: Willingness to Pursue and Utilize Nonideal Donor Livers Among US Donation Service Areas

Transplant Direct. 2021 Aug 6;7(9):e742. doi: 10.1097/TXD.0000000000001173.eCollection 2021 Sep.

Samantha E Halpern¹, Mariya L Samoylova², Brian I Shaw², Samuel J Kesseli², Matthew G Hartwig², Yuval A Patel³, Lisa M McElroy², Andrew S Barbas²

79.

'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs

Addict Sci Clin Pract. 2021 Aug 12;16(1):52. doi: 10.1186/s13722-021-00260-8.

Judith I Tsui¹, Michael P Barry^2 3, Elizabeth J Austin^4 5, Elsa W Sweek^4 5 6, Elyse Tung^7 8, Ryan N Hansen^7 8, Michael Ninburg⁹, John D Scott¹⁰, Sara N Glick^11 3, Emily C Williams^5 6

80.

Prevalence of Hepatitis C Virus Infection Identified From Nontargeted Screening Among Adult Visitors in an Academic Appalachian Regional Emergency Department

Open Forum Infect Dis. 2021 Aug 4;8(8):ofab374. doi: 10.1093/ofid/ofab374.eCollection 2021 Aug.

J Daniel Moore¹, James Galbraith², Roger Humphries¹, Jennifer R Havens³

81.

Hepatitis C virus treatment with direct-acting antivirals induces rapid changes in the hepatic proteome

Viral Hepat. 2021 Nov;28(11):1614-1623. doi: 10.1111/jvh.13593. Epub 2021 Aug 19.

Lauren E Ball¹, Bernice Agana¹, Susana Comte-Walters¹, Don C Rockey², Henry Masur³, Shyam Kottilil⁴, Eric G Meissner^5 6

82.

Medically treated opioid overdoses among New Jersey Medicaid beneficiaries: Rapid growth and complex comorbidity amid growing fentanyl penetration

J Subst Abuse Treat. 2021 Dec;131:108546. doi: 10.1016/j.jsat.2021.108546. Epub 2021 Jun 24.

Stephen Crystal¹, Molly Nowels², Mark Olfson³, Hillary Samples⁴, Arthur Robinson Williams⁵, Peter Treitler⁶

83.

Partnering With State Health Departments to Address Injection-Related Infections During the Opioid Epidemic: Experience at a Safety Net Hospital

Open Forum Infect Dis. 2021 Apr 27;8(8):ofab208. doi: 10.1093/ofid/ofab208.eCollection 2021 Aug.

Rebecca H Burns¹, Cassandra M Pierre^2 3, Jai G Marathe^2 3, Glorimar Ruiz-Mercado^3 4, Jessica L Taylor^5 4, Simeon D Kimmel^3 5, Samantha L Johnson³, H Dawn Fukuda⁶, Sabrina A Assoumou^2 3

84.

Validity of Self-Reported Hepatitis C Virus Status Among Criminal Justice-Involved Persons Living With HIV

J Correct Health Care. 2021 Sep;27(3):167-171. doi: 10.1089/jchc.19.05.0045. Epub 2021 Aug 18.

Amanda Noska^1 2 3, Tao Liu⁴, Irene Kuo⁵, Lauri Bazerman², Ann Kurth⁶, Mia Coetzer¹, Rami Kantor^1 2, Curt Beckwith^1 2

85.

Strategic treatment optimization for HCV (STOPHCV1): a randomized controlled trial of ultrashort duration therapy for chronic hepatitis C

Wellcome Open Res. 2021 Jul 29;6:93. doi: 10.12688/wellcomeopenres.16594.2.eCollection 2021.

Graham S Cooke^1 2, Sarah Pett^3 4 5, Leanne McCabe³, Chris Jones^1 2, Richard Gilson^4 5, Sumita Verma⁶, Stephen D Ryder⁷, Jane D Collier⁸, Stephen T Barclay⁹, Aftab Ala¹⁰, Sanjay Bhagani¹¹, Mark Nelson¹², Chinlye Ch'Ng¹³, Ben Stone¹⁴, Martin Wiselka¹⁵, Daniel Forton¹⁶, Stuart McPherson¹⁷, Rachel Halford¹⁸, Dung Nguyen¹⁹, David Smith¹⁹, Azim Ansari¹⁹, Emily Dennis³, Fleur Hudson³, Eleanor J Barnes^19 20, Ann Sarah Walker³

86.

Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison

Int J Drug Policy. 2021 Oct;96:103394. doi: 10.1016/j.drugpo.2021.103394. Epub 2021 Aug 17.

Zoe Ward¹, Nyashadzaishe Mafirakureva², Jack Stone², Mary Keevans³, Graham Betts-Symonds⁴, Desmond Crowley⁵, Tina McHugh⁶, Gordana Avramovic⁷, John S Lambert⁸, Peter Vickerman²

87.

Changes in health-related quality of life for HCV-infected people who inject drugs on opioid agonist treatment following sustained virologic response

Clin Infect Dis. 2021 Jul 31;ciab669. doi: 10.1093/cid/ciab669.

Mirinda Ann Gormley¹, Matthew J Akiyama², Lior Rennert¹, Kerry A Howard¹, Brianna L Norton², Irene Pericot-Valverde³, Sam Muench², Moonseong Heo¹, Alain H Litwin^3 4 5

88.

Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population

Kidney Int Rep. 2021 Apr 25;6(7):1788-1798. doi: 10.1016/j.ekir.2021.04.015.eCollection 2021 Jul.

Arun Rajasekaran¹, Ricardo A Franco², Edgar T Overton², Brendan M McGuire³, Graham C Towns¹, Jayme E Locke⁴, Deirdre L Sawinski⁵, Emmy K Bell¹

89.

Drug-Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study

Int J Environ Res Public Health. 2021 Jul 3;18(13):7144.doi: 10.3390/ijerph18137144.

Alessandra Mangia¹, Francesco Scaglione², Pierluigi Toniutto³, Mario Pirisi⁴, Nicola Coppola⁵, Giovanni Di Perri⁶, Gema Alvarez Nieto⁷, Stefano Calabrese⁷, Candido Hernandez⁸, Valentina Perrone⁹, Luca Degli Esposti⁹, Stefano Fagiuoli¹⁰

90.

Prospective cohort study of children exposed to hepatitis C virus through a pregnancy screening program

Int J Infect Dis. 2021 Sep;110:62-68. doi: 10.1016/j.ijid.2021.07.019. Epub 2021 Jul 14.

Raquel Borges Pinto¹, Ana Regina L Ramos¹, Leidy Tovar Padua², Emma Jane Swayze³, Mary Catherine Cambou⁴, Maristela Fiorini⁵, Marineide Melo⁶, Breno Riegel Santos⁶, Ivete Cristina Teixeira Canti⁶, Mara Liane Rieck Silveira⁶, Maria Inês Gonzalez Solari⁷, Juliana Ferraz de Correa⁷, Kara Chew⁴, Ivana Rosângela Dos Santos Varella⁶, Karin Nielsen-Saines⁸

91.

Impact of Chronic Hepatitis C virus co-infection on outcomes of infective endocarditis in people who inject drugs

Diagn Microbiol Infect Dis. 2021 Oct;101(2):115453. doi: 10.1016/j.diagmicrobio.2021.115453.Epub 2021 Jun 12.

Chloe Tom¹, Glen Huang², Alexander J Kovalic³, Kyle A Davis⁴, James E Peacock⁵

92.

Hepatitis C in healthcare personnel: follow-up analysis of treatments with direct-acting antiviral agents

J Occup Med Toxicol. 2021 Aug 24;16(1):34. doi: 10.1186/s12995-021-00320-4.

Claudia Westermann¹, Dana Wendeler², Albert Nienhaus^3 2

93.

Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort

Int J Drug Policy. 2021 Oct;96:103422.doi: 10.1016/j.drugpo.2021.103422. Epub 2021 Aug 21.

Joanne M Carson¹, Behzad Hajarizadeh², Josh Hanson³, James O'Beirne⁴, David Iser⁵, Phillip Read⁶, Anne Balcomb⁷, Jane Davies⁸, Joseph S Doyle⁹, Jasmine Yee², Marianne Martinello¹⁰, Philippa Marks², Gregory J Dore¹¹, Gail V Matthews¹¹, REACH-C Study Group

94.

Use of telehealth to increase treatment access for prisoners with chronic hepatitis C

Intern Med J. 2021 Aug;51(8):1344-1347. doi: 10.1111/imj.15451.

Abir Halder¹, Vicky Guizhi Li¹, Marilyn Sebastian¹, Saroja Nazareth¹, Rhoda Tuma¹, Wendy Cheng¹, Adam Doyle¹

95.

A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign

J Viral Hepat. 2021 Nov;28(11):1624-1634.doi: 10.1111/jvh.13596. Epub 2021 Aug 28.

Anna Y Palmer¹, Kico Chan¹, Judy Gold^1 2, Chloe Layton¹, Imogen Elsum¹, Margaret Hellard^{1 2 3 4 5}, Mark Stoove^1 2, Joseph S Doyle^1 3, Alisa Pedrana^1 2, Nick Scott^1 2, on the EC Partnership

96.

Sofosbuvir-Velpatasvir (Epclusa)-Associated Photosensitivity in a Hepatitis C Patient: Case Report and Review of Photosensitivity to Hepatitis C Antiviral Agents

Cureus. 2021 Jul 19;13(7):e16496. doi: 10.7759/cureus.16496.eCollection 2021 Jul.

Stephen E Glombicki¹, Philip R Cohen²

97.

Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta-analysis

J Viral Hepat. 2021 Oct;28(10):1340-1354. doi: 10.1111/jvh.13574. Epub 2021 Jul 31.

Mohammad T Yousafzai¹, Sahar Bajis¹, Maryam Alavi¹, Jason Grebely¹, Gregory J Dore¹, Behzad Hajarizadeh¹

98.

Adherence to clinical follow-up recommendations for liver function tests: A cross-sectional study of patients with HCV and their associated risk behaviors

Prev Med Rep. 2021 Jul 6;23:101482. doi: 10.1016/j.pmedr.2021.101482. eCollection 2021 Sep.

Allison Dormanesh¹, Judy Huei-Yu Wang², Ranit Mishori³, Paula Cupertino⁴, Joshua Longcoy², Seble Kassaye⁵, Linda Kaljee⁶, Coleman Smith⁷, Christopher A Loffredo²

99.

The Impact of Treatment Delay on Hepatitis C Liver Transplant Outcomes

J Pharm Pract. 2021 Jul 21;8971900211034261. doi: 10.1177/08971900211034261.Online ahead of print.

Ian A Booth¹, Jacqueline E Clark¹, John C LaMattina², Rolf N Barth², Abdolreza Haririan³, Bharath R Ravichandran¹

100.

Practice Patterns of Family Physicians With and Without Addiction Medicine Board Certification

J Am Board Fam Med. Jul-Aug 2021;34(4):814-819. doi: 10.3122/jabfm.2021.04.200456.

Sebastian T Tong¹, Zachary J Morgan², Andrew W Bazemore², Aimee R Eden², Ruchi M Fitzgerald², Lars E Peterson²

101.

Sofosbuvir/Velpatasvir For The Treatment Of Hepatitis C In Pediatric Patients

Expert Rev Gastroenterol Hepatol. 2021 Oct;15(10):1097-1105.doi: 10.1080/17474124.2021.1963231. Epub 2021 Aug 19.

Chiara Rubino¹, Sandra Trapani², Giuseppe Indolfi^1 3

102.

High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study

Open Forum Infect Dis. 2021 Jun 9;8(7):ofab267. doi: 10.1093/ofid/ofab267. eCollection 2021 Jul.

Barnaby Flower^1 2, Leanne McCabe³, Chau Le Ngoc¹, Hung Le Manh⁴, Phuong Le Thanh⁴, Thuan Dang Trong⁴, Thu Vo Thi¹, Hang Vu Thi Kim¹, Thanh Nguyen Tat¹, Dao Phan Thi Hong¹, An Nguyen Thi Chau¹, Tan Dinh Thi¹, Nga Tran Thi Tuyet¹, Joel Tarning⁵, Cherry Kingsley², Evelyne Kestelyn¹, Sarah L Pett³, Guy Thwaites¹, Vinh Chau Nguyen Van⁴, David Smith⁶, Eleanor Barnes⁶, M Azim Ansari⁶, Hugo Turner⁷, Motiur Rahman¹, Ann Sarah Walker², Jeremy Day¹, Graham S Cooke²

103.

Mechanisms of HCV resistance to broadly neutralizing antibodies

Curr Opin Virol. 2021 Oct;50:23-29. doi: 10.1016/j.coviro.2021.07.003.Epub 2021 Jul 28.

Nicole Frumento¹, Andrew I Flyak², Justin R Bailey³

104.

Hepatitis C virus care cascade in persons experiencing homelessness in the United States in the era of direct-acting antiviral agents: A scoping review

J Viral Hepat. 2021 Nov;28(11):1506-1514. doi: 10.1111/jvh.13583. Epub 2021 Aug 11.

Aubrey Del Rosario¹, Jonathan D Eldredge¹, Sara Doorley¹, Shiraz I Mishra¹, Denece Kesler¹, Kimberly Page¹

105.

Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 years follow-up of a prospective longitudinal study

J Viral Hepat. 2021 Nov;28(11):1604-1613. doi: 10.1111/jvh.13587. Epub 2021 Oct 1.

Viola Knop¹, Daniel Hoppe^1 2, Johannes Vermehren¹, Sven Troetschler^1 3, Eva Herrmann⁴, Annika Vermehren¹, Mireen Friedrich-Rust¹, Christoph Sarrazin^1 5, Jonel Trebicka¹, Stefan Zeuzem¹, Martin-Walter Welker¹

106.

Identification of Genetically Related HCV Infections Among Self-Described Injecting Partnerships

Clin Infect Dis. 2021 Aug 27;ciab596. doi: 10.1093/cid/ciab596. Online ahead of print.

Damien C Tully^1 2, Judith A Hahn³, David J Bean⁴, Jennifer L Evans⁵, Meghan D Morris⁵, Kimberly Page⁶, Todd M Allen⁴

107.

Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials

J Viral Hepat. 2021 Nov;28(11):1635-1642. doi: 10.1111/jvh.13600. Epub 2021 Sep 8.

Edward Gane¹, Victor de Ledinghen^2 3, Douglas E Dylla⁴, Giuliano Rizzardini⁵, Mitchell L Shiffman⁶, Stephen T Barclay⁷, Jose Luis Calleja⁸, Zhenyi Xue⁴, Margaret Burroughs⁴, Julio A Gutierrez⁹

108.

Modeling Hepatitis C Elimination Among People Who Inject Drugs in New Hampshire

JAMA Netw Open. 2021 Aug 2;4(8):e2119092. doi: 10.1001/jamanetworkopen.2021.19092.

Andrew Blake¹, James E Smith²

109.

Hepatitis C Virus Vaccine Research: Time to Put Up or Shut Up

Viruses. 2021 Aug 12;13(8):1596. doi: 10.3390/v13081596.

Alex S Hartlage^1 2, Amit Kapoor^1 3

110.

Podcasts for the Delivery of Medical Education and Remote Learning

J Med Internet Res. 2021 Aug 27;23(8):e29168. doi: 10.2196/29168.

Julliana Newman¹, Andrew Liew², Jon Bowles³, Kelly Soady⁴, Steven Inglis²

111.

Is Hodgkin Lymphoma Associated with Hepatitis B and C Viruses? A Systematic Review and Meta-analysis

Cancer Epidemiol Biomarkers Prev. 2021 Sep 20.doi: 10.1158/1055-9965.EPI-21-0548. Online ahead of print.

Callum J R Mullen^# 1, Karena D Volesky^# 2, Zoë R Greenwald³, Mariam El-Zein², Eduardo L Franco²

112.

High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence

Am J Gastroenterol. 2021 Sep 1;116(9):1896-1904. doi: 10.14309/ajg.0000000000001332.

Philippe J Zamor¹, Ashley Brown², Douglas E Dylla³, John F Dillon⁴, Anne F Luetkemeyer⁵, Jordan J Feld⁶, David Mutimer⁷, Reem Ghalib⁸, Eric Crown³, Sandra S Lovell³, Yiran Hu³, Christophe Moreno⁹, David R Nelson¹⁰, Massimo Colombo¹¹, Georgios Papatheodoridis¹², Juergen K Rockstroh¹³, Richard Skoien¹⁴, Eric Lawitz¹⁵, Ira M Jacobson¹⁶

113.	Strategies To Maximize Study Retention And Limit Attrition Bias In A Prospective Cohort Study Of Men Reporting A History Of Injecting Drug Use Released From Prison: The Prison And Transition Health Study
	Ashleigh Cara Stewart^1 2, Reece Cossar^3 4, Shelley Walker³, Anna Lee Wilkinson^3 5, Brendan Quinn^3 5, Paul Dietze^3 5 6, Rebecca Winter^3 7, Amy Kirwan³, Michael Curtis^3 5 8, James R P Ogloff⁴, Stuart Kinner^{5 9 10 11 12}, Campbell Aitken^3 5, Tony Butler¹³, Emma Woods³, Mark Stoové^3 5

114.

Machine-learning-based predictions of direct-acting antiviral therapy duration for patients with hepatitis C

Int J Med Inform. 2021 Oct;154:104562. doi: 10.1016/j.ijmedinf.2021.104562. Epub 2021 Aug 26.

Theodore C Feldman¹, Jules L Dienstag², Kenneth D Mandl³, Yi-Ju Tseng⁴

115.

Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation

Ann Surg. 2021 Oct 1;274(4):613-620. doi: 10.1097/SLA.0000000000005070.

Michael K Turgeon¹, Shimul A Shah², Aaron M Delman², Benjamin V Tran³, Vatche G Agopian³, Joel P Wedd¹, Joseph F Magliocca¹, Ahyoung Kim⁴, Andrew Cameron⁴, Ali Olyaei⁵, Susan L Orloff⁵, Matthew P Anderson⁶, Chandrashekhar A Kubal⁶, Robert M Cannon⁷, Jayme E Locke⁷, Mary A Simpson⁸, Mohamed E Akoad⁸, Chelsey P Wongjirad⁹, Juliet Emamaullee⁹, Amika Moro¹⁰, Federico Aucejo¹⁰, Cyrus A Feizpour¹¹, Parsia A Vagefi¹¹, Mindie H Nguyen¹², Carlos O Esquivel¹², Kiran Dhanireddy¹³, Vijay Subramanian¹³, Alejandro Chavarriaga¹⁴, Marwan M Kazimi¹⁴, Maia S Anderson¹⁵, Christopher J Sonnenday¹⁵, Steven C Kim¹⁶, David P Foley¹⁶, Marwan Abdouljoud¹⁷, Reena J Salgia¹⁷, Dimitrios Moris¹⁸, Debra L Sudan¹⁸, Swaytha R Ganesh¹⁹, Abhinav Humar¹⁹, Majella Doyle²⁰, William C Chapman²⁰, Shishir K Maithel¹

116.

Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications

PLoS One. 2021 Sep 16;16(9):e0257369. doi: 10.1371/journal.pone.0257369. eCollection 2021.

Jisoo A Kwon¹, Gregory J Dore¹, Behzad Hajarizadeh¹, Maryam Alavi¹, Heather Valerio¹, Jason Grebely¹, Rebecca Guy¹, Richard T Gray¹

117.

Adaptive Challenges and Family Support: Patient Self-Management during Treatment for Chronic Hepatitis C

Nurs Sci Q. 2021 Oct;34(4):405-412. doi: 10.1177/08943184211031602.

Donald E Bailey Jr¹, Andrew J Muir², Michael P Cary Jr¹, Natalie Ammarell³, Sarah Seaver⁴, Emily Scirica¹, Mitch Mah'moud⁵, Ruth A Anderson⁶

118.

Non-adherence to LDV/SOF did not predict SVR in a randomized controlled trial of HIV/HCV coinfected persons who use drugs

Infect Dis. 2021 Sep 20;jiab477. doi: 10.1093/infdis/jiab477.

Kathleen M Ward¹, Oluwaseun Falade-Nwulia¹, Juhi Moon¹, Catherine G Sutcliffe², Sherilyn Brinkley¹, Taryn Haselhuhn¹, Stephanie Katz¹, Kayla Herne¹, Lilian Arteaga¹, Shruti H Mehta², Carl Latkin³, Robert K Brooner⁴, Mark S Sulkowski¹

119.

Impact of COVID-19-related public health measures on HCV testing in British Columbia, Canada: An interrupted time series analysis

Liver Int. 2021 Sep 30. doi: 10.1111/liv.15074. Online ahead of print.

Mawuena Binka¹, Sofia Bartlett^1 2, Héctor A Velásquez García¹, Maryam Darvishian³, Dahn Jeong^1 4, Prince Adu^1 4, Maria Alvarez¹, Stanley Wong¹, Amanda Yu¹, Hasina Samji^1 5, Mel Krajden^1 2, Jason Wong^1 4, Naveed Z Janjua^1 4

120.

Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation

Liver Int. 2021 Sep 28. doi: 10.1111/liv.15070. Online ahead of print.

Andrea Marcellusi^1 2, Francesco Saverio Mennini^1 2, Murad Ruf³, Claudio Galli⁴, Alessio Aghemo^5 6, Maurizia R Brunetto^7 8, Sergio Babudieri⁹, Antonio Craxi¹⁰, Massimo Andreoni^11 12, Loreta A Kondili¹³

121.

Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: A multicentre prospective study

J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13617. Online ahead of print.

Valerio Rosato¹, Antonio Ascione², Riccardo Nevola³, Anna Ludovica Fracanzani⁴, Guido Piai⁵, Vincenzo Messina⁶, Ernesto Claar¹, Carmine Coppola⁷, Luca Fontanella², Rosa Lombardi⁴, Laura Staiano⁷, Giovanna Valente⁵, Maria Chiara Fascione³, Chiara Giorgione³, Annalisa Mazzocca³, Raffaele Galiero³, Pasquale Perillo¹, Aldo Marrone³, Ferdinando Carlo Sasso³, Luigi Elio Adinolfi³, Luca Rinaldi³

122.

Effects of direct-acting antiviral treatment on reducing mortality among Medicare beneficiaries with HIV and HCV coinfection

AIDS Care. 2021 Sep 28;1-8. doi: 10.1080/09540121.2021.1981221. Online ahead of print.

Xin Yin¹, Lan Kong¹, Ping Du², Jeah Jung³

123.

Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study

Dig Liver Dis. 2021 Sep 27;S1590-8658(21)00776-3. doi: 10.1016/j.dld.2021.09.007.Online ahead of print.

Vincenza Calvaruso¹, Salvatore Petta², Donatella Ferraro³, Claudia La Mantia², Gerlando Gibilaro², Giada Reina², Velia Chiara Di Maio⁴, Anna Licata⁵, Francesca Ceccherini-Silberstein⁴, Vito Di Marco², Antonio Craxì²

124.

Cancer in People with and without Hepatitis C Virus Infection: Comparison of Risk Before and After Introduction of Direct-Acting Antivirals

Cancer Epidemiol Biomarkers Prev. 2021 Sep 28. doi: 10.1158/1055-9965.EPI-21-0742.Online ahead of print.

Jennifer O Lam¹, Leo B Hurley², Jennifer B Lai³, Varun Saxena^4 5, Suk Seo^6 7, Scott Chamberland⁸, Charles P Quesenberry Jr², Jamila H Champsi⁴, Joanna Ready⁹, Elizabeth Y Chiao^10 11 12, Julia L Marcus^# 13, Michael J Silverberg^# 2

125.

Impact of COVID-19 on Prescribing Trends of Direct-Acting Antivirals for the Treatment of Hepatitis C in Ontario, Canada

Am J Gastroenterol. 2021 Aug 1;116(8):1738-1740.doi: 10.14309/ajg.0000000000001287.

Natalia Konstantelos^1 2, Ahmad Shakeri¹, Daniel McCormack³, Jordan J Feld^4 5, Tara Gomes^2 3 6, Mina Tadrous^1 2 3

126.

How can general practitioners support people who inject drugs to engage with direct-acting antiviral treatment for hepatitis C? A qualitative study

Aust J Gen Pract. 2021 Oct;50(10):716-721. doi: 10.31128/AJGP-03-21-5899.

Emma Heard¹, Andrew Smirnov², Luciana Massi³, Linda A Selvey⁴

127.

J Hepatol. 2021 Sep 29;S0168-8278(21)02084-5. doi: 10.1016/j.jhep.2021.09.023.Online ahead of print.

Patrice Cacoub¹, Cloé Comarmond², Matheus Vieira³, Paul Régnier³, David Saadoun³

128.

Changes in clinical scenarios, management, and perspectives of patients with chronic hepatitis C after viral clearance by direct-acting antivirals

Expert Rev Gastroenterol Hepatol. 2021 Jun;15(6):643-656.doi: 10.1080/17474124.2021.1877136. Epub 2021 Feb 15.

Riccardo Nevola¹, Luca Rinaldi¹, Letizia Zeni¹, Ciro Romano¹, Aldo Marrone¹, Raffaele Galiero¹, Pia Clara Pafundi¹, Carlo Acierno¹, Erica Vetrano¹, Luigi Elio Adinolfi¹

129.

Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs

J Hepatol. 2021 Oct 8;S0168-8278(21)02103-6. doi: 10.1016/j.jhep.2021.09.038.Online ahead of print.

Alan Yeung¹, Norah E Palmateer², John F Dillon³, Scott A McDonald², Shanley Smith², Stephen Barclay⁴, Peter C Hayes⁵, Rory N Gunson⁶, Kate Templeton⁷, David J Goldberg⁸, Matthew Hickman⁹, Sharon J Hutchinson²

130.

Turning the tide on hepatitis C-related liver transplantation: the return on investment in hepatitis C treatment in Australia and New Zealand

Liver Transpl. 2021 Oct 8. doi: 10.1002/lt.26329. Online ahead of print.

Jess Howell^1 2 3 4, Avik Majumdar^5 6, Michael Fink^7 8, Mandy Byrne⁷, Geoff McCaughan^5 6, Simone I Strasser^5 6, Michael Crawford^5 6, Peter Hodgkinson⁹, Katherine A Stuart⁹, Caroline Tallis⁹, John Chen¹⁰, Alan Wigg¹⁰, Robert Jones^7 8, Bryon Jaques¹¹, Gary Jeffrey^11 12, Leon Adams^11 12, Michael C Wallace^11 12, Stephen Munn¹³, Ed Gane^13 14, Alex Thompson^1 2, Paul Gow^1 7

131.

Evaluating the Effectiveness of the AIDS Education and Training Center (AETC) National Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Curriculum

J Med Educ Curric Dev. 2021 Sep 30;8:23821205211041178. doi: 10.1177/23821205211041178.eCollection Jan-Dec 2021.

Waridibo E Allison¹, Aro N Choi¹, Keito Kawasaki¹, Trisha V Melhado¹

132.

BMS-986263 in Patients with Advanced Hepatic Fibrosis: 36-Week Results from a Randomized, Placebo-Controlled Phase 2 Trial

Hepatology. 2021 Oct 4. doi: 10.1002/hep.32181. Online ahead of print.

Eric J Lawitz¹, Diane E Shevell², Giridhar S Tirucherai², Shuyan Du², Warner Chen², Uma Kavita², Angie Coste¹, Fred Poordad¹, Morten Karsdal³, Mette Nielsen³, Zachary Goodman⁴, Edgar D Charles²

133.

Adherence to Hepatitis C Therapy in a Shelter-Based Education and Treatment Model Among Persons Experiencing Homelessness

Open Forum Infect Dis. 2021 Sep 25;8(10):ofab488. doi: 10.1093/ofid/ofab488.eCollection 2021 Oct.

Jesse Powell¹, Margaret Ricco¹, Jessica Naugle², Catherine Magee³, Hayat Hassan¹, Carmen Masson⁴, Grace Braimoh¹, Barry Zevin², Mandana Khalili^3 5

134.

Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure

Nat Commun. 2021 Oct 20;12(1):6105. doi: 10.1038/s41467-021-25649-6.

David A Smith¹, Carlota Fernandez-Antunez², Andrea Magri¹, Rory Bowden³, Nimisha Chaturvedi⁴, Jacques Fellay^4 5 6, John McLauchlan⁷, Graham R Foster⁸, William L Irving⁹, STOP-HCV Consortium; Peter Simmonds¹, Vincent Pedergnana¹⁰, Santseharay Ramirez², Jens Bukh², Eleanor Barnes¹, M Azim Ansari^11 12

135.

Hepatitis C core antigen test as an alternative for diagnosing HCV infection: mathematical model and cost-effectiveness analysis

PeerJ. 2021 Sep 10;9:e11895. doi: 10.7717/peerj.11895. eCollection 2021.

Maryam Sadeghimehr¹, Barbara Bertisch^1 2, Francesco Negro³, Maia Butsashvili⁴, Sonjelle Shilton⁵, Irina Tskhomelidze⁶, Maia Tsereteli⁷, Olivia Keiser¹, Janne Estill^1 8

136.

Experiences and Perspectives From Women Taking Investigational Therapy for Hepatitis C Virus During Pregnancy

Subst Abuse. 2021 Sep 28;15:11782218211046261. doi: 10.1177/11782218211046261.eCollection 2021.

Yasaswi Kislovskiy^1 2, Catherine Chappell^2 3, Emily Flaherty⁴, Megan E Hamm⁵, Flor de Abril Cameron⁵, Elizabeth E Krans^2 3, Judy C Chang^2 3

137.

Incidence of liver and non-liver-related outcomes in patients with HCV-cirrhosis after SVR

J Hepatol. 2021 Sep 27;S0168-8278(21)02043-2. doi: 10.1016/j.jhep.2021.09.013.Online ahead of print.

Roberta D'Ambrosio¹, Elisabetta Degasperi², Maria Paola Anolli², Ilaria Fanetti², Marta Borghi², Roberta Soffredini², Massimo Iavarone², Giulia Tosetti², Riccardo Perbellini², Angelo Sangiovanni², Vana Sypsa³, Pietro Lampertico⁴

138.

Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections

Transplant Direct. 2021 Sep 7;7(10):e762. doi: 10.1097/TXD.0000000000001222.eCollection 2021 Oct.

Zoe A Stewart¹, Jeffrey Stern¹, Nicole M Ali¹, Harmit S Kalia¹, Karen Khalil¹, Srijana Jonchhe¹, Elaina P Weldon¹, Rebecca A Dieter¹, Tyler C Lewis¹, Nur Funches¹, Sudara Crosby¹, Monique Seow¹, Jonathan C Berger¹, Nabil N Dagher¹, Bruce E Gelb¹, Anthony C Watkins¹, Nader Moazami¹, Deane E Smith¹, Zachary N Kon², Stephanie H Chang¹, Alex Reyentovich¹, Luis F Angel¹, Robert A Montgomery¹, Bonnie E Lonze¹

139.

Kidney Transplantation From Hepatitis C Viremic Deceased Donors to Aviremic Recipients in a Real-world Setting

Transplant Direct. 2021 Sep 7;7(10):e761. doi: 10.1097/TXD.0000000000001217.eCollection 2021 Oct.

Beatrice P Concepcion¹, Laura A Binari¹, Heidi Schaefer¹, Scott Rega², Irene Feurer², Saed Shawar¹, Ruchi Naik³, Laura Hickman⁴, Jasmine Walker⁴, Meghan Kapp⁵, Kelly A Birdwell¹, Anthony Langone¹, J Harold Helderman¹, Bonnie Ann Sarrell¹, Guneet Kochar¹, Bernard Dubray⁴, Kristin Smith⁶, Heather O'Dell⁶, April DeMers⁶, Princess Shelton⁶, Roman Perri⁷, David Shaffer⁴, Rachel C Forbes⁴

140.

Enhancing Linkage to Hepatitis C Virus Treatment Following Pregnancy in Women Identified During Perinatal Care

Hepatol Commun. 2021 Sep;5(9):1543-1554. doi: 10.1002/hep4.1748. Epub 2021 Jul 1.

Rachel L Epstein^1 2, Carole Moloney², Jacob Garfinkel³, Kelley Saia⁴, Elisha M Wachman⁵, Sara Lodi⁶, Stephen I Pelton²

141.

Telemedicine in Hepatology: Current Applications and Future Directions

Liver Transpl. 2021 Sep 10. doi: 10.1002/lt.26293. Online ahead of print.

Brian M Fung¹², Megan Perumpail³, Yuval A Patel⁴, James H Tabibian⁵⁶

142.

Treatment and prevention of viral hepatitis in pregnancy

Am J Obstet Gynecol. 2021 Sep 10;S0002-9378(21)00998-4.doi: 10.1016/j.ajog.2021.09.002. Online ahead of print.

Jodie Dionne-Odom¹, Gabriella D Cozzi², Ricardo A Franco³, Basile Njei⁴, Alan T N Tita⁵

143.

Disparities in Treatment with Direct-Acting Hepatitis C Virus Antivirals Persist Among Adults Coinfected with HIV and Hepatitis C Virus in US Clinics, 2010-2018

AIDS Patient Care STDS. 2021 Oct;35(10):392-400. doi: 10.1089/apc.2021.0087.

Gina M Simoncini¹, Qingjiang Hou², Kimberly Carlson², Kate Buchacz³, Ellen Tedaldi¹, Frank Palella , Jr⁴, Marcus Durham³, Jun Li³, HIV Outpatient Study (HOPS) Investigators

144.

Testing for Hepatitis C Virus Infection Among Adults Aged =18 in the United States, 2013-2017

Public Health Rep. 2021 Oct 4;333549211047236. doi: 10.1177/00333549211047236.Online ahead of print.

Hope King¹, J E Soh^1 2, William W Thompson¹, Jessica Rogers Brown¹, Karina Rapposelli¹, Claudia Vellozzi¹

145.

Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system

Drug Alcohol Depend. 2021 Sep 25;228:109050. doi: 10.1016/j.drugalcdep.2021.109050.Online ahead of print.

Daisy Gibbs¹, Olivia Price², Jason Grebely³, Sarah Larney⁴, Rachel Sutherland², Phillip Read⁵, Kerryn Butler⁶, Louisa Degenhardt², Amy Peacock⁷

146.

The impact of disease-related knowledge on perceptions of stigma among patients with Hepatitis C Virus (HCV) infection

PLoS One. 2021 Oct 5;16(10):e0258143. doi: 10.1371/journal.pone.0258143. eCollection 2021.

M Elle Saine^1 2, Julia E Szymczak¹, Tyler M Moore³, Laura P Bamford⁴, Frances K Barg^1 5, Kimberly A Forde⁶, Jason Schnittker^2 7, John H Holmes¹, Nandita Mitra^1 2, Vincent Lo Re 3rd^1 8

147.

Louisiana Medicaid access for treatment and care for hepatitis C virus (LA-MATCH) project: A cross-sectional study protocol

PLoS One. 2021 Oct 6;16(10):e0257437. doi: 10.1371/journal.pone.0257437. eCollection 2021.

Hasheemah Afaneh¹, Susanne Straif-Bourgeois¹, Evrim Oral², Ashley Wennerstrom³, Olivia Sugarman³, William T Robinson³, Angel Whittington⁴, Edward Trapido¹

148.

Hepatitis C infection and complication rates after total shoulder arthroplasty in United States veterans

JSES Int. 2021 Apr 20;5(4):699-706. doi: 10.1016/j.jseint.2021.02.009. eCollection 2021 Jul.

Favian Su¹, Charles J Cogan¹, Ilya Bendich¹, Ning Zhang^2 3, Mary A Whooley^2 3 4, Alfred C Kuo^1 5

149.

Implementing opt-out hepatitis C virus (HCV) screening in Canadian provincial prisons: A model-based cost-effectiveness analysis

Int J Drug Policy. 2021 Jun 24;103345. doi: 10.1016/j.drugpo.2021.103345. Online ahead of print.

Léa Duchesne¹, Camille Dussault², Arnaud Godin³, Mathieu Maheu-Giroux³, Nadine Kronfli⁴

150.

Increasing multiorgan heart transplantation with hepatitis C virus donors in the current-era

J Heart Lung Transplant. 2021 May 29;S1053-2498(21)02328-7.doi: 10.1016/j.healun.2021.05.018. Online ahead of print.

Shivank Madan¹, Snehal R Patel², Peter Vlismas², Vagish Hemmige³, Omar Saeed², Daniel J Goldstein⁴, Ulrich P Jorde²

151.

Discovery and Optimization of a 4-Aminopiperidine Scaffold for Inhibition of Hepatitis C Virus Assembly

J Med Chem. 2021 Jul 8;64(13):9431-9443. doi: 10.1021/acs.jmedchem.1c00696.Epub 2021 Jun 29.

Adam Rolt¹, Daniel C Talley², Seung Bum Park¹, Zongyi Hu¹, Andrés Dulcey², Christopher Ma¹, Parker Irvin¹, Madeleine Leek¹, Amy Q Wang², Andrew V Stachulski³, Xin Xu², Noel Southall², Marc Ferrer², T Jake Liang¹, Juan J Marugan²

152.

Is the Availability of Direct-Acting Antivirals Associated with Increased Access to Hepatitis C Treatment for Homeless and Unstably Housed Veterans?

J Gen Intern Med. 2021 Jun 25. doi: 10.1007/s11606-021-06933-z. Online ahead of print.

D Keith McInnes^1 2, Lara K Troszak^3 4, B Graeme Fincke^5 6, Michael Shwartz⁷, Amanda M Midboe^3 4, Allen L Gifford^7 8, Shawn Dunlap⁵, Thomas Byrne^5 9

153.

A cost-effectiveness analysis of universal hepatitis C screening in all United States pregnancies

J Matern Fetal Neonatal Med. 2021 Aug 16;1-8. doi: 10.1080/14767058.2021.1949442.Online ahead of print.

Marguerite Susich¹, Alyssa R Hersh¹, Karen Greiner¹, Sarina R Chaiken¹, Aaron B Caughey¹

154.

Hepatitis C virus infection and anesthesia practice: A narrative review

Anaesth Intensive Care. 2021 Aug 11;310057X211016004. doi: 10.1177/0310057X211016004.Online ahead of print.

Jeremy A Carman¹, Karl Kh Lee¹, Andrew I Gardner², Smathi Kk Chong^2 3

155.

Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction-A Real-world Experience

Open Forum Infect Dis. 2021 Jun 17;8(8):ofab325. doi: 10.1093/ofid/ofab325.eCollection 2021 Aug.

Lisa Sandmann¹, Julian Deppe^2 3, Christoph Beier¹, Valerie Ohlendorf¹, Julia Schneider¹, Heiner Wedemeyer^1 4, Felix Wedegärtner², Markus Cornberg^1 4 5, Benjamin Maasoumy^1 4 5

156.

Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis

Hepatology. 2021 Jul;74(1):72-82. doi: 10.1002/hep.31700. Epub 2021 Jun 15.

Freya Wellhöner¹, Nico Döscher¹, Franziska Woelfl¹, Marius Vital², Iris Plumeier², Silke Kahl², Andrej Potthoff¹, Michael Peter Manns^1 3, Dietmar Helmut Pieper^2 3, Markus Cornberg^1 3, Heiner Wedemeyer^1 3, Benjamin Heidrich^1 2 3

157.

Updated Evidence on the Epidemiology of Hepatitis C Virus in Hemodialysis

Pathogens. 2021 Sep 7;10(9):1149. doi: 10.3390/pathogens10091149.

Fabrizio Fabrizi¹, Roberta Cerutti¹, Piergiorgio Messa^1 2

158.

"That was quick, simple, and easy": Patient perceptions of acceptability of point-of-care hepatitis C RNA testing at a reception prison

Int J Drug Policy. 2021 Sep 21;99:103456. doi: 10.1016/j.drugpo.2021.103456.Online ahead of print.

Lise Lafferty¹, Amanda Cochrane², Yumi Sheehan³, Carla Treloar⁴, Jason Grebely³, Andrew R Lloyd³

159.

Access to hepatitis C direct-acting antiviral therapy in hepatitis C-positive donor to hepatitis C-negative recipient solid-organ transplantation in a real-world setting

Am J Surg. 2021 Sep 14;S0002-9610(21)00528-6. doi: 10.1016/j.amjsurg.2021.09.005.Online ahead of print.

Cori Edmonds¹, Alicia Carver², Josh DeClercq³, Leena Choi⁴, Megan Peter⁵, Kelly Schlendorf⁶, Roman Perri⁷, Rachel C Forbes⁸, Beatrice P Concepcion⁹

160.

All-cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy

J Gastroenterol Hepatol. 2021 Sep 14. doi: 10.1111/jgh.15687. Online ahead of print.

Ian Lockart^1 2, Behzad Hajarizadeh³, Niamh Buckley², Scott Davison^4 5, Emilia Prakoso^4 6, Miriam T Levy^4 5, Jacob George⁷, Gregory J Dore^2 3, Mark Danta^1 2

161.

Outcomes in Hepatitis C Positive Liver Transplantation: Timing of Direct-Acting Antiviral Treatment and Impact on Graft Fibrosis

Viruses. 2021 Sep 14;13(9):1831.doi: 10.3390/v13091831.

Jennifer Wellington¹, Andrew Ma², Shyam Kottilil³, Bharath Ravichandran⁴, Jennifer Husson³, David Bruno⁵, Eleanor Wilson³

162.

An evaluation of ledipasvir + sofosbuvir for the treatment of chronic hepatitis C infection

Expert Opin Pharmacother. 2021 Jul 1;1-8. doi: 10.1080/14656566.2021.1943359.Online ahead of print.

Pearson Balatow¹, Amber Sandlin¹, Theodore James Cory¹

163.

The Relationship Between Hepatitis C Virus Rates and Office-Based Buprenorphine Access in Ohio

Open Forum Infect Dis. 2021 May 17;8(6):ofab242. doi: 10.1093/ofid/ofab242.eCollection 2021 Jun.

Daniel L Brook^1 2, Angela T Hetrick¹, Shibani R Chettri¹, Christine A Schalkoff³, Adams L Sibley³, Kathryn E Lancaster¹, Vivian F Go³, William C Miller¹, David M Kline⁴

164.

Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings : Harm Reduction in Outpatient Addiction Treatment

J Gen Intern Med. 2021 Jun 22;1-10. doi: 10.1007/s11606-021-06904-4.Online ahead of print.

Jessica L Taylor^1 2, Samantha Johnson^3 4, Ricardo Cruz^5 3, Jessica R Gray^6 7, Davida Schiff⁸, Sarah M Bagley^5 3 9

165.

Exploring how hospitalization can alter hepatitis c virus treatment prioritization and trajectories in people who use drugs: A qualitative analysis

Subst Abus. 2021 Jun 23;1-8. doi: 10.1080/08897077.2021.1932699. Online ahead of print.

Ximena A Levander¹, Taylor A Vega², Andrew Seaman^1 3, P Todd Korthuis¹, Honora Englander^1 4

166.

HepCCATT: a multilevel intervention for hepatitis C among vulnerable populations in Chicago

J Public Health (Oxf). 2021 Jun 22;fdab190. doi: 10.1093/pubmed/fdab190. Online ahead of print.

Sandra Tilmon¹, A Aronsohn², B Boodram³, L Canary⁴, S Goel⁵, T Hamlish⁶, S Kemble⁷, D S Lauderdale⁸, J Layden⁹, K Lee¹, A J Millman⁴, N Nelson⁴, K Ritger¹⁰, I Rodriguez¹, N Shurupova¹¹, J Wolf¹², D Johnson¹

167.

Upscaling HIV and hepatitis C testing in primary healthcare settings: stigma-sensitive practice

Aust J Prim Health. 2021 Aug;27(4):255-258. doi: 10.1071/PY20176.

Emily Lenton¹, Jen Johnson², Graham Brown³

168.

Is elimination of HCV realistic by 2030: France

Liver Int. 2021 Jun;41 Suppl 1:45-49. doi: 10.1111/liv.14862.

Stanislas Pol¹, Loriane Lair-Mehiri¹, Anaïs Vallet-Pichard¹

169.

Is elimination of HCV in 2030 realistic in Central Europe

Liver Int. 2021 Jun;41 Suppl 1:56-60. doi: 10.1111/liv.14834.

Robert Flisiak¹, Dorota Zarebska-Michaluk², Sona Frankova³, Ivica Grgurevic⁴, Bela Hunyady⁵, Peter Jarcuska⁶, Limas Kupcinskas⁷, Michael Makara⁸, Marieta Simonova⁹, Jan Sperl³, Ieva Tolmane¹⁰, Adriana Vince¹¹

170.

Is elimination of hepatitis C virus realistic by 2030: Eastern Europe

Liver Int. 2021 Jun;41 Suppl 1:50-55. doi: 10.1111/liv.14836.

Vasily Isakov¹, Vladimir Tsyrkunov², Dmitry Nikityuk^1 3

171.

Hepatitis C Virus Core Antigen (HCVAg): an affordable assay to monitor the efficacy of treatment in DAAs era

New Microbiol. 2021 Apr;44(2):89-94. Epub 2021 May 21.

Barbara Rossetti¹, Elisabetta Loggi^2 3, Chiara Spertilli Raffaelli⁴, Simona Mercinelli¹, Claudia Gandolfo⁵, Gianni Gori Savellini⁵, Silvia Galli⁶, Giovanni Vitale^2 7, Roberto Di Donato², Ranka Vukotic², Elena Grandini², Marzia Margotti², Valeria Guarneri², Giuliano Furlini⁶, Maria Carla Re⁶, Andrea De Luca^1 4, Pietro Andreone^2 8, Claudio Galli⁹, Maria Grazia Cusi⁵

172.

Personal, provider and system level barriers and enablers for hepatitis C treatment in the era of direct-acting antivirals: Experiences of patients who inject drugs accessing treatment in general practice settings in Australia

J Subst Abuse Treat. 2021 Aug;127:108460. doi: 10.1016/j.jsat.2021.108460. Epub 2021 May 8.

Emma Heard¹, Andrew Smirnov², Luciana Massi³, Linda A Selvey⁴

173.

Direct antiviral agents in hepatitis C virus related liver disease: Don

World J Gastroenterol. 2021 Jun 7;27(21):2771-2783. doi: 10.3748/wjg.v27.i21.2771.

Stella Compagnoni¹, Erica Maria Bruno¹, Giorgio Madonia², Marco Cannizzaro³, Salvatore Madonia⁴

174.

Key Elements on the Pathway to HCV Elimination: Lessons Learned From the AASLD HCV Special Interest Group 2020

Hepatol Commun. 2021 May 3;5(6):911-922. doi: 10.1002/hep4.1731.eCollection 2021 Jun.

Jordan J Feld¹, John W Ward²

175.

A nurse-led, telehealth-driven hepatitis C management initiative in regional Victoria: Cascade of care from referral to cure

J Telemed Telecare. 2021 Jun 18;1357633X211024108. doi: 10.1177/1357633X211024108.Online ahead of print.

Beverly Rodrigues¹, Nola Parsons¹, James Haridy¹, Stephen Bloom^1 2, Caroline Day¹, Geoffrey Haar¹, Amanda Nicoll^1 2, Rohit Sawhney^1 2

176.

Facilitating engagement of persons with opioid use disorder in treatment for hepatitis C virus infection via telemedicine: Stories of onsite case managers

J Subst Abuse Treat. 2021 Aug;127:108421. doi: 10.1016/j.jsat.2021.108421. Epub 2021 Apr 21.

Andrew H Talal¹, Urmo Jaanimägi², Kathleen Davis³, Jordan Bailey⁴, Barbara M Bauer², Arpan Dharia², Saliyah George⁵, Anthony McLeod⁴, Karen Morton⁶, Ann Nugent⁵, Marija Zeremski⁶, Amreen Dinani⁵, Don C Des Jarlais⁷, Ponni V Perumalswami⁸, Jonathan N Tobin⁶, Suzanne S Dickerson⁹

177.

Developing and Piloting a Standardized European Protocol for Hepatitis C Prevalence Surveys in the General Population (2016-2019)

Front Public Health. 2021 May 28;9:568524. doi: 10.3389/fpubh.2021.568524. eCollection 2021.

Ida Sperle^1 2, Stine Nielsen³, Viviane Bremer¹, Martyna Gassowski¹, Henrikki Brummer-Korvenkontio⁴, Roberto Bruni⁵, Anna Rita Ciccaglione⁵, Elena Kaneva⁶, Kirsi Liitsola⁴, Zlatina Naneva⁶, Tanya Perchemlieva⁶, Enea Spada⁵, Salla E Toikkanen⁴, Andrew J Amato-Gauci⁷, Erika Duffell⁷, Ruth Zimmermann¹

178.

The impact of current opioid agonist therapy on hepatitis C virus treatment initiation among people who use drugs from in the DAA era: A population-based study

Clin Infect Dis. 2021 Jun 14;ciab546. doi: 10.1093/cid/ciab546. Online ahead of print.

Sofia R Bartlett^1 2, Stanley Wong¹, Amanda Yu¹, Margo Pearce^1 3, Julia MacIsaac⁴, Susan Nouch^5 6, Prince Adu^1 3, James Wilton¹, Hasina Samji^1 7, Emilia Clementi^1 3, Hector Velasquez¹, Dahn Jeong^1 3, Mawuena Binka¹, Maria Alvarez¹, Jason Wong^1 3, Jane Buxton^1 3, Mel Krajden^1 2, Naveed Z Janjua^1 3

179.

Outcomes of hepatitis C virus nucleic acid testing positive donors in aviremic recipients with delayed direct-acting antiviral initiation

Clin Transplant. 2021 Jun 16;e14386. doi: 10.1111/ctr.14386. Online ahead of print.

Madeline R Hudson¹, Allyssa R Webb¹, Angela Tong Logan¹, Andrew Silverman¹, Andrew J Brueckner¹

180.

"Sobriety equals getting rid of hepatitis C": A qualitative study exploring the interplay of substance use disorder and hepatitis C among hospitalized adults

J Subst Abuse Treat. 2021 Aug;127:108337. doi: 10.1016/j.jsat.2021.108337. Epub 2021 Feb 25.

Taylor A Vega¹, Ximena A Levander², Andrew Seaman³, P Todd Korthuis⁴, Honora Englander⁵

181.

Associations of HCV Knowledge and Medical Mistrust with Being Screened for HCV and Offered HCV Treatment among People with HIV

J Health Care Poor Underserved. 2021;32(2):1019-1033. doi: 10.1353/hpu.2021.0077.

Laura M Bogart, Vivian L Towe, Erik D Storholm, Lisa Wagner, Rebecca Weir, Sara Woody, Susan Robilotto

182.

"Raising HOPE": Improved Outcomes for HIV/HCV-coinfected Liver Transplant Recipients in the Direct-acting Antiviral Era

Transplant Direct. 2021 Jun 8;7(7):e707. doi: 10.1097/TXD.0000000000001154.eCollection 2021 Jul.

Thomas G Cotter¹, Jennifer Wang¹, Sarah R Lieber², Matthew A Odenwald¹, Nicole E Rich², Jorge A Marrero², Amit G Singal², Mack C Mitchell², Andrew Aronsohn¹, Michael Charlton¹, John Fung²

183.

A nurse practitioner model of care in the era of direct acting antiviral therapy for hepatitis C virus infection

JGH Open. 2021 May 20;5(6):669-672. doi: 10.1002/jgh3.12552. eCollection 2021 Jun.

Steffanie Nario¹, Benhur Reynauld¹, Helen Blacklaws¹, Sharon Boden¹, Rishi Sud¹, Glenn Hawken¹, Satbir Singh¹, Karl Herba¹, James Panetta¹, James Pang¹

184.

Universal Screening for Hepatitis C Virus in the ED Using a Best Practice Advisory

West J Emerg Med. 2021 May 14;22(3):719-725. doi: 10.5811/westjem.2021.1.49667.

James S Ford¹, Tasleem Chechi¹, Kavian Toosi¹, Bilawal Mahmood¹, Dillon Meehleis¹, Michella Otmar¹, Nam Tran², Larissa May¹

185.

Liver health events: an indigenous community-led model to enhance HCV screening and linkage to care

Health Promot Int. 2021 Jun 13;daab074. doi: 10.1093/heapro/daab074. Online ahead of print.

Mamata Pandey¹, Stephanie Konrad², Noreen Reed³, Vanessa Ahenakew³, Patricia Isbister³, Tanys Isbister³, Lesley Gallagher⁴, Trisha Campbell⁵, Stuart Skinner^5 6

186.

Sociodemographic characteristics associated with hepatitis C among patients admitted for medically managed opioid withdrawal in east Tennessee

J Addict Dis. 2021 Jun 13;1-4. doi: 10.1080/10550887.2021.1935187. Online ahead of print.

Ryan Alexander^1 2, Olayinka Agboola¹, Victoria Costales^1 3 4

187.

Society for Maternal-Fetal Medicine Consult Series #56: hepatitis C in pregnancy-updated guidelines: Replaces Consult Number 43, November 2017

Am J Obstet Gynecol. 2021 Jun 8;S0002-9378(21)00639-6. doi: 10.1016/j.ajog.2021.06.008.Online ahead of print.

Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org¹; Sarah K Dotters-Katz¹, Jeffrey A Kuller¹, Brenna L Hughes¹

188.

Utilizing patient perception of group treatment in exploring medication adherence, social support, and quality of life outcomes in people who inject drugs with hepatitis C

J Subst Abuse Treat. 2021 Jul;126:108459. doi: 10.1016/j.jsat.2021.108459. Epub 2021 May 7.

Kerry A Howard¹, Lior Rennert¹, Irene Pericot-Valverde², Moonseong Heo¹, Brianna L Norton³, Matthew J Akiyama³, Linda Agyemang³, Alain H Litwin⁴

189.

Medicaid Expansion Association With End-Stage Liver Disease Mortality Depends on Leniency of Medicaid Hepatitis C Virus Coverage

Liver Transpl. 2021 Jun 12. doi: 10.1002/lt.26209. Online ahead of print.

Nabeel A Wahid¹, Jihui Lee², Alyson Kaplan^1 3, Brett E Fortune^1 3, Monika M Safford^1 4, Robert S Brown Jr^1 3, Russell Rosenblatt^1 3

190.

Effects of the Kentucky Hepatitis Academic Mentorship Program on Hepatitis C Treatment in a Federally Qualified Health Center

J Health Care Poor Underserved. 2021;32(2):664-670. doi: 10.1353/hpu.2021.0095.

Katherine Crabtree

191.

Using vibration controlled transient elastography and FIB-4 to assess liver cirrhosis in a hepatitis C virus infected population

Medicine (Baltimore). 2021 Jun 11;100(23):e26200. doi: 10.1097/MD.0000000000026200.

Nabil Saleem¹, Lesley S Miller¹, Alia S Dadabhai¹, Emily J Cartwright^1 2

192.

The estimated hepatitis C seroprevalence and key population sizes in San Diego in 2018

PLoS One. 2021 Jun 9;16(6):e0251635. doi: 10.1371/journal.pone.0251635. eCollection 2021.

Adriane Wynn¹, Samantha Tweeten², Eric McDonald², Wilma Wooten², Kimberley Lucas³, Cassandra L Cyr¹, Maricris Hernandez¹, Franchesca Ramirez⁴, Corey VanWormer⁵, Scott Suckow⁶, Christian B Ramers⁷, Natasha K Martin¹

193.

Program Adaptations to Provide Harm Reduction Services During the COVID-19 Pandemic: A Qualitative Study of Syringe Services Programs in the U.S

AIDS Behav. 2021 Jun 10;1-12. doi: 10.1007/s10461-021-03332-7. Online ahead of print.

Madeline C Frost^1 2, Elsa W Sweek¹, Elizabeth J Austin¹, Maria A Corcorran³, Alexa M Juarez³, Noah D Frank³, Stephanie M Prohaska⁴, Paul A LaKosky⁴, Alice K Asher⁵, Dita Broz⁶, Don C Des Jarlais⁷, Emily C Williams^1 2, Sara N Glick⁸

194.

Hepatitis C virus screening of high-risk patients in a community hospital emergency department: Retrospective review of patient characteristics and future implications

PLoS One. 2021 Jun 10;16(6):e0252976. doi: 10.1371/journal.pone.0252976. eCollection 2021.

Ji Seok Park^1 2, Judy Wong³, Hillary Cohen³

195.

Comparison of hepatitis C treatment outcomes between primary care and specialty care

J Am Assoc Nurse Pract. 2021 Jun 9. doi: 10.1097/JXX.0000000000000621.Online ahead of print.

Kate Stanley¹, Bonnie H Bowie

196.

Trends in homelessness and injection practices among young urban and suburban people who inject drugs: 1997-2017

Drug Alcohol Depend. 2021 Aug 1;225:108797. doi: 10.1016/j.drugalcdep.2021.108797.Epub 2021 May 29.

Anna Hotton¹, Mary-Ellen Mackesy-Amiti², Basmattee Boodram³

197.

Decreases in Hepatitis C Testing and Treatment During the COVID-19 Pandemic

Am J Prev Med. 2021 May 10;S0749-3797(21)00220-8. doi: 10.1016/j.amepre.2021.03.011.Online ahead of print.

Harvey W Kaufman¹, Lara Bull-Otterson², William A Meyer 3rd³, Xiaohua Huang³, Mona Doshani⁴, William W Thompson⁴, Ademola Osinubi⁴, Mohammed A Khan⁴, Aaron M Harris⁴, Neil Gupta⁴, Michelle Van Handel⁴, Carolyn Wester⁴, Jonathan Mermin⁴, Noele P Nelson⁴

198.

Soluble CD163 Identifies Those at Risk for Increased Hepatic Inflammation & Fibrosis

Open Forum Infect Dis. 2021 Apr 22;8(6):ofab203. doi: 10.1093/ofid/ofab203.eCollection 2021 Jun.

Kenneth E Sherman¹, Heidi L Meeds¹, Susan D Rouster¹, Enass A Abdel-Hameed¹, Jacqueline Hernandez², Javier Tamargo², Jun Chen³, Richard L Ehman³, Marianna Baum²

199.

Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study

J Manag Care Spec Pharm. 2021 Jun 9;1-10. doi: 10.18553/jmcp.2021.20550.Online ahead of print.

Michael P Curry¹, Steven L Flamm², Scott Milligan³, Naoky Tsai⁴, Nicole Wick³, Zobair Younossi⁵, Nezam H Afdhal¹

200.

Evaluating the prevention benefit of HCV treatment: Modelling the SToP-C treatment as prevention study in prisons

Hepatology. 2021 Jun 9. doi: 10.1002/hep.32002. Online ahead of print.

Aaron G Lim¹, Jack Stone¹, Behzad Hajarizadeh², Marianne Byrne², Georgina M Chambers³, Natasha K Martin⁴, Jason Grebely², Gregory J Dore², Andrew R Lloyd², Peter Vickerman¹

201.

Best practice recommendations for the use of hepatitis C viremic donor organs for hepatitis C virus naïve recipients

Clin Transplant. 2021 Jun 4;e14381. doi: 10.1111/ctr.14381. Online ahead of print.

Zoe A Stewart¹, Shimul A Shah², Jason A Rolls³, James V Guarrera⁴, Raja Kandaswamy⁵, David A Axelrod⁶

202.

Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience

Am J Gastroenterol. 2021 Jun 1;116(6):1248-1255.doi: 10.14309/ajg.0000000000001147.

Luca Rinaldi¹, Vincenzo Messina², Vito Di Marco³, Vincenzo Iovinella⁴, Ernesto Claar⁵, Giuseppe Cariti⁶, Rodolfo Sacco⁷, Massimo De Luca⁸, Gaetano Scifo⁹, Pietro Gatti¹⁰, Giorgio Barbarini¹¹, Valeria Pace Palitti¹², Mariano Quartini¹³, Paolo Tundo¹⁴, Gianpiero D'Offizi¹⁵, Giustino Parruti¹⁶, Maria Antonietta di Rosolini¹⁷, Giovanni Garrucciu¹⁸, Lucio Cosco¹⁹, Francesco Benanti²⁰, Giancarlo Gimignani²¹, Umberto Vespasiani Gentilucci²², Francesco Di Lorenzo²³, Maria D'Antò²⁴, Riccardo Nevola¹, Tommaso Lupia⁶, Valerio Rosato⁵, Valeria Morbiducci¹³, Ilaria Luzzitelli¹⁵, Federica Sozio¹⁶, Marco Di Stefano⁹, Emanuela Ciraci¹⁰, Fabio Bulla¹⁹, Riccardo Guarisco²¹, Cecilia Cangiano¹, Michele Imparato²⁵, Paolo Maggi², Antonio Ascione²⁵, Antonio Craxì³, Antonio Izzi²⁶

203.

Reflections on project ECHO: qualitative findings from five different ECHO programs

Med Educ Online. 2021 Dec;26(1):1936435. doi: 10.1080/10872981.2021.1936435.

Jon Agley¹, Janet Delong¹, Andrea Janota², Anyé Carson², Jeffrey Roberts¹, Gerardo Maupome³

204.

Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis

JAMA Psychiatry. 2021 Jun 2;e210976. doi: 10.1001/jamapsychiatry.2021.0976.Online ahead of print.

Thomas Santo Jr¹, Brodie Clark¹, Matt Hickman², Jason Grebely³, Gabrielle Campbell^1 4, Luis Sordo^5 6, Aileen Chen^1 7, Lucy Thi Tran¹, Chrianna Bharat¹, Prianka Padmanathan², Grainne Cousins⁸, Julie Dupouy^9 10, Erin Kelty¹¹, Roberto Muga¹², Bohdan Nosyk^13 14, Jeong Min¹³, Raimondo Pavarin^15 16, Michael Farrell¹, Louisa Degenhardt¹

205.

Primary Care Providers in Federally Qualified Health Centers Can Treat Hepatitis C Effectively Without Ongoing Consultative Support From Specialists

Med Care. 2021 Jun 3. doi: 10.1097/MLR.0000000000001582. Online ahead of print.

Richard A Moore 2nd¹, Michael W Fried, Brad Wright

206.

Structure-Based and Rational Design of a Hepatitis C Virus Vaccine

Viruses. 2021 May 5;13(5):837. doi: 10.3390/v13050837.

Johnathan D Guest^1 2, Brian G Pierce^1 2

207.

"It's time!": A qualitative exploration of the acceptability of hepatitis C notification systems to help eliminate hepatitis C

Int J Drug Policy. 2021 May 28;97:103280. doi: 10.1016/j.drugpo.2021.103280.Online ahead of print.

Shelley Walker¹, Jack Wallace², Ned Latham², Freya Saich², Alisa Pedrana³, Margaret Hellard⁴, Carla Treloar⁵, Tafireyi Marukutira², Peter Higgs⁶, Joseph Doyle⁷, Mark Stoové³

208.

Effectiveness of the HCV blood screening strategy through eighteen years of surveillance of HCV infection in blood donors in France

Blood Transfus. 2021 May 12. doi: 10.2450/2021.0032-21. Online ahead of print.

Pierre Cappy¹, Laure Boizeau¹, Daniel Candotti¹, Rémi Caparros¹, Quentin Lucas¹, Eliane Garrabe², Christophe Martinaud², Sophie Le Cam³, Pierre Gallian^3 4, Pascal Morel^3 5, Josiane Pillonel⁶, Syria Laperche¹

209.

Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019

Infez Med. 2021 Jun 1;29(2):242-251.

Barbara Rossetti¹, Lorenzo Paglicci², Velia C Di Maio³, Chiara Cassol², Silvia Barbaliscia³, Stefania Paolucci⁴, Bianca Bruzzone⁵, Nicola Coppola⁶, Francesca Montagnani², Valeria Micheli⁷, Laura Monno⁸, Giacomo Zanelli², Teresa Santantonio⁹, Nunzia Cuomo¹⁰, Cinzia Caudai¹¹, Maurizio Zazzi¹², Francesca Ceccherini-Silberstein³, C On Behalf Of The Hcv Virology Italian Resistance Network Vironet

210.

Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV)

PLoS Med. 2021 Jun 1;18(6):e1003653. doi: 10.1371/journal.pmed.1003653.eCollection 2021 Jun.

Lars T Fadnes^1 2, Christer Frode Aas^1 2, Jørn Henrik Vold^1 2, Rafael Alexander Leiva³, Christian Ohldieck¹, Fatemeh Chalabianloo^1 2, Svetlana Skurtveit^4 5, Ole Jørgen Lygren^1 6, Olav Dalgård^7 8, Peter Vickerman⁹, Håvard Midgard^7 10, Else-Marie Løberg^1 11 12, Kjell Arne Johansson^1 2, INTRO-HCV Study Group

211.

Clinical comparison between trial participants and potentially eligible patients using electronic health record data: A generalizability assessment method

J Biomed Inform. 2021 May 25;119:103822. doi: 10.1016/j.jbi.2021.103822. Online ahead of print.

James R Rogers¹, George Hripcsak², Ying Kuen Cheung³, Chunhua Weng⁴

212.

Injecting network structure determines the most efficient strategy to achieve Hepatitis C elimination in people who inject drugs

J Viral Hepat. 2021 May 28. doi: 10.1111/jvh.13554. Online ahead of print.

Chloe Brown¹, Martin Siegele², Mark Wright³, Charlotte Cook¹, Julie Parkes¹, Salim I Khakoo¹, Rachel Sacks-Davis⁴, Ryan M Buchanan¹

213.

Using the electronic medical record to increase testing for HIV and hepatitis C virus in an Appalachian emergency department

BMC Health Serv Res. 2021 May 29;21(1):524. doi: 10.1186/s12913-021-06482-5.

Carmen N Burrell^1 2, Melinda J Sharon³, Stephen Davis^3 4, Judith Feinberg^5 6, Elena M Wojcik³, Julia Nist⁷, Owen Lander³, Valerie Boley⁸, Justin Burns³, Ian B K Martin⁹

214.

Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes

Nutr Metab Cardiovasc Dis. 2021 May 1;S0939-4753(21)00186-1.doi: 10.1016/j.numecd.2021.04.016. Online ahead of print.

Ferdinando Carlo Sasso¹, Pia Clara Pafundi², Alfredo Caturano², Raffaele Galiero², Erica Vetrano², Riccardo Nevola², Salvatore Petta³, Anna Ludovica Fracanzani⁴, Carmine Coppola⁵, Vito Di Marco³, Antonio Solano⁶, Rosa Lombardi⁴, Mauro Giordano², Antonio Craxi³, Alessandro Perrella⁷, Celestino Sardu², Raffaele Marfella², Teresa Salvatore⁸, Luigi Elio Adinolfi², Luca Rinaldi⁹

215.

Progress in hepatitis C virus management in chronic kidney disease

Curr Opin Nephrol Hypertens. 2021 May 28. doi: 10.1097/MNH.0000000000000729.Online ahead of print.

Abraham Cohen-Bucay¹, Jean M Francis, Craig E Gordon

216.

Outcomes of a Pharmacist-Led Hepatitis C Virus Treatment Program in an Urban Safety-Net Health System, Chicago, 2017-2019

Public Health Rep. 2021 May 27;333549211015664.

.doi: 10.1177/00333549211015664.Online ahead of print.

Bijou R Hunt¹, Hollyn Cetrone², Sharon Sam¹, Nancy R Glick^1 3

217.

Hepatitis C Virus in Neonates and Infants

Clin Perinatol. 2021 Jun;48(2):343-357.doi: 10.1016/j.clp.2021.03.007.

Rachel L Epstein¹, Claudia Espinosa²

218.

Association of hepatitis C infection and acute coronary syndrome: A case-control study

Medicine (Baltimore). 2021 May 28;100(21):e26033. doi: 10.1097/MD.0000000000026033.

Angela Wu¹, Shana Burrowes², Erin Zisman¹, Todd Tarquin Brown³, Shashwatee Bagchi^4 5

219.

An outbreak of hepatitis C virus attributed to the use of multi-dose vials at a colonoscopy clinic, Waterloo Region, Ontario

Can Commun Dis Rep. 2021 May 7;47(4):224-231. doi: 10.14745/ccdr.v47i04a07.

Arianne Folkema¹, Hsiu-Li Wang^1 2, Kristy Wright¹, M Mustafa Hirji^2 3, Anton Andonov⁴, Kathryn Bromley¹, Chad Ludwig¹, Amy MacArthur¹

220.

The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs

J Hepatol. 2021 Jul;75 Suppl 1:S3-S13. doi: 10.1016/j.jhep.2020.11.042.

Peter Jepsen¹, Zobair M Younossi²

221.

Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts

Adv Ther. 2021 Jun;38(6):3409-3426. doi: 10.1007/s12325-021-01753-3. Epub 2021 May 22.

Xavier Forns¹, Jordan J Feld², Douglas E Dylla³, Stanislas Pol⁴, Kazuaki Chayama⁵, Jinlin Hou⁶, Jeong Heo⁷, Pietro Lampertico^8 9, Ashley Brown¹⁰, Mark Bondin³, Fernando Tatsch³, Margaret Burroughs³, John Marcinak³, Zhenzhen Zhang³, Amanda Emmett³, Stuart C Gordon¹¹, Ira M Jacobson¹²

222.

Hepatitis-Induced Porphyria: Are Direct-Acting Antiviral Agents the Way of the Future?

ACG Case Rep J. 2021 May 14;8(5):e00581.doi: 10.14309/crj.0000000000000581. eCollection 2021 May.

Jason J John¹, Richard K Sterling²

223.

Sofosbuvir, glecaprevir, pibrentasvir, and ribavirin as a rescue therapy in difficult-to-treat hepatitis C patients

Hepatology. 2021 May 18. doi: 10.1002/hep.31909. Online ahead of print.

Magdalena Meszaros¹, Régine Truchi², Denis Ouzan³, Albert Tran², Marc Bourliere⁴, Georges Philippe Pageaux¹

224.

Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection

J Hepatol. 2021 May 20;S0168-8278(21)00336-6. doi: 10.1016/j.jhep.2021.04.056.Online ahead of print.

Gail V Matthews¹, Sanjay Bhagani², Marc Van der Valk³, Juergen Rockstroh⁴, Jordan J Feld⁵, Andri Rauch⁶, Christine Thurnheer⁶, Julie Bruneau⁷, Arthur Kim⁸, Margaret Hellard⁹, David Shaw¹⁰, Ed Gane¹¹, Mark Nelson¹², Patrick Ingiliz¹³, Tanya L Applegate¹⁴, Jason Grebely¹⁴, Phillipa Marks¹⁴, Marianne Martinello¹⁴, Kathy Petoumenos¹⁴, Gregory J Dore¹⁵, REACT study group; Protocol Steering Committee; Marc van der Valk¹⁶, Margaret Hellard¹⁷, Ed Gane¹¹, Andri Rauch¹⁸, Julie Bruneau⁷, Arthur Kim¹⁹, Sanjay Bhagani²⁰, Greg Dore²¹, Pip Marks²², Gail Matthews²², Jason Grebely²², Kathy Petoumenos²², Marianne Martinello²², Tanya Applegate²², Jordan Feld²³, Jürgen Rockstroh⁴, Coordinating Centre; Site Principal Investigators

Collaborators

Gail Matthews²⁴, Pip Marks²⁴, Sophia Amjad²⁴, Elise Tu²⁴, Kathy Petoumenos²⁴, Mahshid Tamaddoni²⁴, Marc van der Valk¹⁶, Margaret Hellard¹⁷, Ed Gane¹¹, Maria Christine Thurnheer¹⁸, Yvonne Gilleece²⁵, Julie Bruneau⁷, Mark Nelson²⁶, Chris Fraser²⁷, Alberto Moriggia²⁸, Thomas Lutz²⁹, Juhi Moon³⁰, Phillip Read³¹, Arthur Y Kim¹⁹, Andrew Ustianowski³², Christiane Cordes³³, David Shaw¹⁰, Sanjay Bhagani²⁰, Joe Sasadeusz³⁴, Mark Hull³⁵, Greg Dore²¹, Jordan Feld²³, Jürgen Rockstroh⁴, Dominique Braun³⁶, Patrick Ingiliz¹³

225.

Linkage of resistance-associated substitutions in GT1 sofosbuvir+NS5A inhibitor failures treated with glecaprevir/pibrentasvir

J Hepatol. 2021 May 20;S0168-8278(21)00339-1. doi: 10.1016/j.jhep.2021.04.057.Online ahead of print.

Gary P Wang¹, Gretja L Schnell², Jens J Kort³, Gurjit S Sidhu⁴, Layla Schuster⁴, Rakesh L Tripathi², Lois Larsen², Larry C Michael⁵, Ken Bergquist⁵, Ashley Magee⁵, Chandni B Patel⁴, Joan A Whitlock⁴, Ryan Tamashiro⁴, Joy A Peter⁶, Michael W Fried⁷, David R Nelson⁸

226.

Adolescent Hepatitis C: Prevalence, Impact, and Management Challenges

Adolesc Health Med Ther. 2021 May 7;12:45-53. doi: 10.2147/AHMT.S263864.eCollection 2021.

Paula Chaves Mari¹, Reema Gulati¹, Philip Fragassi¹

227.

Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality

J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13543. Online ahead of print.

Scott A McDonald¹, Stephen T Barclay², Hamish A Innes¹, Andrew Fraser³, Peter C Hayes⁴, Andrew Bathgate⁴, John F Dillon⁵, April Went⁶, David J Goldberg¹, Sharon J Hutchinson¹

228.

Cost-effectiveness of total state coverage for hepatitis C medications

Am J Manag Care. 2021 May 1;27(5):e171-e177. doi: 10.37765/ajmc.2021.88640.

William V Padula^# 1, Jonathan S Levin^#, Joy Lee, Gerard F Anderson

229.

Real World SOF/VEL/VOX Retreatment Outcomes and Viral Resistance Analysis for HCV Patients with Prior Failure to DAA Therapy

J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13549. Online ahead of print.

David A Smith^1 2, Daniel Bradshaw³, Jean Mbisa³, Carmen F Manso³, David Bibby³, Josh Singer⁴, Emma Thomson⁴, Ana Filipe⁴, Elihu Aranday-Cortes⁴, M Azim Ansari¹, Anthony Brown¹, Emma Hudson¹, Jennifer Benselin⁵, Brendan Healy⁶, Phil Troke⁷, John McLauchlan⁴, Eleanor Barnes^1 2, William L Irving⁵

230.

Behavioral interventions to improve population health outreach for hepatitis C screening: randomized clinical trial

BMJ. 2021 May 18;373:n1022. doi: 10.1136/bmj.n1022.

Shivan J Mehta^1 2, Susan C Day³, Anne H Norris³, Jessica Sung^3 2, Catherine Reitz^3 2, Colin Wollack⁴, Christopher K Snider², Pamela A Shaw⁵, David A Asch^3 2 6

231.

Metabolic and cardiovascular complications after virological cure in hepatitis C: What awaits beyond

World J Gastroenterol. 2021 May 7;27(17):1959-1972. doi: 10.3748/wjg.v27.i17.1959.

Mohamed Shengir¹, Mohamed Elgara², Giada Sebastiani³

232.

Paradigm Shift in Utilization of Livers from Hepatitis C-Viremic Donors into Hepatitis C Virus-Negative Patients

Clin Liver Dis. 2021 Feb;25(1):195-207. doi: 10.1016/j.cld.2020.08.009.Epub 2020 Nov 5.

Eric F Martin¹

233.

Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease

Am J Gastroenterol. 2021 Apr;116(4):723-732. doi: 10.14309/ajg.0000000000000994.

Monica Pons¹, Salvador Augustin, Bernhard Scheiner, Maeva Guillaume, Matteo Rosselli, Susana G Rodrigues, Horia Stefanescu, Mang M Ma, Mattias Mandorfer, Mayka Mergeay-Fabre, Bogdan Procopet, Philipp Schwabl, Arnulf Ferlitsch, Georg Semmler, Annalisa Berzigotti, Emmanuel Tsochatzis, Christophe Bureau, Thomas Reiberger, Jaime Bosch, Juan G Abraldes, Joan Genescà

234.

Characteristics and Donation Outcomes of Potential Organ Donors Perceived to be at Increased Risk for Blood Borne Virus Transmission: an Australian Cohort Study 2010-2018

Transplantation. 2021 Feb 22. doi: 10.1097/TP.0000000000003715. Online ahead of print.

Karen M J Waller¹, Nicole L De La Mata, Brenda M Rosales, James A Hedley, Patrick J Kelly, Imogen K Thomson, Michael J O'Leary, Elena Cavazzoni, Vidiya Ramachandran, William D Rawlinson, Kate R Wyburn, Angela C Webster

235.

Center-level Utilization of Hepatitis C Virus Positive Donors for Orthotopic Heart Transplantation

Transplantation. 2021 Feb 8. doi: 10.1097/TP.0000000000003674. Online ahead of print.

Lauren V Huckaby¹, Laura M Seese, Robert Handzel, Yisi Wang, Gavin Hickey, Arman Kilic

236.

Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens

J Hepatol. 2021 May 8;S0168-8278(21)00310-X. doi: 10.1016/j.jhep.2021.04.045.Online ahead of print.

Rajiv Shah¹, Lucrece Ahovegbe², Marc Niebel¹, James Shepherd¹, Emma C Thomson³

237.

Paradigm Shift in Utilization of Livers from Hepatitis C-Viremic Donors into Hepatitis C Virus-Negative Patients

Clin Liver Dis. 2021 Feb;25(1):195-207. doi: 10.1016/j.cld.2020.08.009.Epub 2020 Nov 5.

Eric F Martin¹

238.

Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease

Am J Gastroenterol. 2021 Apr;116(4):723-732. doi: 10.14309/ajg.0000000000000994.

239.

Characteristics and Donation Outcomes of Potential Organ Donors Perceived to be at Increased Risk for Blood Borne Virus Transmission: an Australian Cohort Study 2010-2018

Transplantation. 2021 Feb 22. doi: 10.1097/TP.0000000000003715. Online ahead of print.

240.

Center-level Utilization of Hepatitis C Virus Positive Donors for Orthotopic Heart Transplantation

Transplantation. 2021 Feb 8. doi: 10.1097/TP.0000000000003674. Online ahead of print.

Lauren V Huckaby¹, Laura M Seese, Robert Handzel, Yisi Wang, Gavin Hickey, Arman Kilic

241.

Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens

J Hepatol. 2021 May 8;S0168-8278(21)00310-X. doi: 10.1016/j.jhep.2021.04.045.Online ahead of print.

Rajiv Shah¹, Lucrece Ahovegbe², Marc Niebel¹, James Shepherd¹, Emma C Thomson³

242.

Inverse probability weighting for selection bias in a Delaware community health center electronic medical record study of community deprivation and hepatitis C prevalence

Ann Epidemiol. 2021 Apr 29;S1047-2797(21)00067-3. doi: 10.1016/j.annepidem.2021.04.011.Online ahead of print.

Neal D Goldstein¹, Deborah Kahal², Karla Testa³, Igor Burstyn⁴

243.

Pragmatic Experience with Risk-based versus Universal Hepatitis C Screening in Pregnancy: Detection of Infection and Postpartum Linkage to Care

Am J Perinatol. 2021 May 2. doi: 10.1055/s-0041-1728827. Online ahead of print.

Elisa T Bushman^1 2, Lakshmi Subramani³, Aalok Sanjanwala^1 2, Jodie Dionne-Odom⁴, Ricardo Franco⁴, John Owen^1 2, Akila Subramaniam^1 2

244.

Elbasvir/grazoprevir administered for 12 weeks via Percutaneous Endoscopic Gastrostomy Tube Achieves Sustained Virologic Response: A Case Report and a Review of the Literature

Pharmacotherapy. 2021 May 2. doi: 10.1002/phar.2531. Online ahead of print.

Rajeev B Shah¹, Katy L Garrett², Amy L Brotherton³, Amanda J Noska⁴

245.

Understanding effect site pharmacology of uprifosbuvir, a HCV nucleoside inhibitor: case study of a multidisciplinary modelling approach in drug development

CPT Pharmacometrics Syst Pharmacol. 2021 May 2. doi: 10.1002/psp4.12644.Online ahead of print.

Paul van den Berg¹, Wei Gao², Maurice J Ahsman¹, Leticia Arrington², Filippos Kesisoglou², Randy Miller², Teun M Post¹, Matthew L Rizk²

246.

Excitable models: Projections, targets, and the making of futures without disease

Sociol Health Illn. 2021 May 4. doi: 10.1111/1467-9566.13263. Online ahead of print.

Tim Rhodes^1 2, Kari Lancaster²

247.

Variation in Participation in Nurse-Driven Emergency Department Hepatitis C Screening

Adv Emerg Nurs J. 2021 Apr-Jun 01;43(2):138-144. doi: 10.1097/TME.0000000000000349.

Bennett H Lane¹, Rachel M Ancona, Michael S Lyons, Brittany E Punches

248.

Alcohol Consumption and Hepatitis C Virus (HCV) RNA Levels in HIV/HCV Coinfected Patients

Viruses. 2021 Apr 21;13(5):716. doi: 10.3390/v13050716.

Daniel Fuster¹, David Nunes², Debbie M Cheng^3 4, Richard Saitz^3 5 6, Jeffrey H Samet^3 5 6

249.

Care cascade of patients with Hepatitis C and HIV identified by Emergency Department screening

J Viral Hepat. 2021 May 1. doi: 10.1111/jvh.13529. Online ahead of print.

Ethan Cowan¹, Joseph Hardardt¹, Samantha Brandspiegel¹, Erick Eiting¹, Yvette Calderon¹

250.

Infectious disease screening in a dedicated primary care clinic for children in foster care

Child Abuse Negl. 2021 Apr 28;117:105074. doi: 10.1016/j.chiabu.2021.105074.Online ahead of print.

Sarah Lairmore¹, Kimberly E Stone², Rong Huang³, Jill McLeigh³

251.

"Stigma is where the harm comes from": Exploring expectations and lived experiences of hepatitis C virus post-treatment trajectories among people who inject drugs

Int J Drug Policy. 2021 Apr 23;103238. doi: 10.1016/j.drugpo.2021.103238. Online ahead of print.

Trevor Goodyear¹, Helen Brown², Annette J Browne², Peter Hoong³, Lianping Ti⁴, Rod Knight⁵

252.

A population-based US study of hepatitis C diagnosis rate

Eur J Gastroenterol Hepatol. 2021 Apr 16. doi: 10.1097/MEG.0000000000002149.Online ahead of print.

Yee Hui Yeo¹, Leslie Y Kam, Michael H Le, Donghak Jeong, Nolan Dang, Linda Henry, Ramsey Cheung, Mindie H Nguyen

253.

T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral Therapy

Open Forum Infect Dis. 2021 Feb 18;8(4):ofab079.doi: 10.1093/ofid/ofab079.eCollection 2021 Apr.

Ann W N Auma¹, Carey Shive¹, Sofi Damjanovska², Corinne Kowal², Daniel E Cohen³, Debika Bhattacharya⁴, Beverly Alston-Smith⁵, Melissa Osborne², Robert Kalayjian², Ashwin Balagopal⁶, Mark Sulkowski⁶, David Wyles⁷, Donald D Anthony^1 2 8

254.

Impact of alcohol on the progression of HCV-related liver disease: A systematic review and meta-analysis

J Hepatol. 2021 Apr 20;S0168-8278(21)00253-1. doi: 10.1016/j.jhep.2021.04.018.Online ahead of print.

Laura Llamosas-Falcón¹, Kevin D Shield², Maya Gelovany³, Omer S M Hasan⁴, Jakob Manthey⁵, Maristela Monteiro⁶, Nick Walsh⁶, Jürgen Rehm⁷

255.

Reaching trans women in San Francisco for efforts to eliminate hepatitis C

J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13521. Online ahead of print.

Christopher J Hernandez¹, Dillon Trujillo¹, Caitlin M Turner^1 2, Sofia Sicro¹, Joaquin Meza¹, Mackie Bella¹, Emperatriz Daza¹, Francisco Torres¹, Willi McFarland^1 2, Erin C Wilson^1 2

256.

Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial

Lancet Gastroenterol Hepatol. 2021 Apr 15;S2468-1253(21)00031-5.doi: 10.1016/S2468-1253(21)00031-5. Online ahead of print.

Isabelle Andrieux-Meyer¹, Soek-Siam Tan², Sombat Thanprasertsuk³, Nicolas Salvadori⁴, Caroline Menétrey⁵, François Simon⁵, Tim R Cressey⁶, Hajjah Rosaida Hj Mohd Said⁷, Muhammad Radzi Abu Hassan⁸, Haniza Omar², Hoi-Poh Tee⁹, Wah Kheong Chan¹⁰, Suresh Kumar¹¹, Satawat Thongsawat¹², Kanawee Thetket¹³, Anchalee Avihingsanon¹⁴, Suparat Khemnark¹⁵, Sabine Yerly¹⁶, Nicole Ngo-Giang-Huong¹⁷, Sasikala Siva¹⁸, Alistair Swanson⁵, Vishal Goyal¹⁹, Francois Bompart⁵, Bernard Pécoul⁵, Shahnaz Murad²⁰

257.

Direct-Acting Antivirals and Organ Transplantation: Is There Anything We Can't Do?

J Infect Dis. 2020 Nov 27;222(Supplement_9):S794-S801. doi: 10.1093/infdis/jiaa420.

Matthew R Kappus¹², Cameron R Wolfe¹², Andrew J Muir¹²

258.

Electronic Health Record Reminder Effect on Hepatitis C Antibody Screening

J Am Board Fam Med. Nov-Dec 2020;33(6):1016-1019. doi: 10.3122/jabfm.2020.06.190440.

Elie Mulhem¹, Indigo Brown¹, Ke Song¹

259.

Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase

Eur J Gastroenterol Hepatol. 2021 Apr 21. doi: 10.1097/MEG.0000000000002173.Online ahead of print.

Kaleen N Hayes¹, Theresa Burkard, Stefan Weiler, Mina Tadrous, Andrea M Burden

260.

Hepatitis C Virus Testing Among Men With Human Immunodeficiency Virus Who Have Sex With Men: Temporal Trends and Racial/Ethnic Disparities

Open Forum Infect Dis. 2021 Apr 17;8(4):ofaa645. doi: 10.1093/ofid/ofaa645.eCollection 2021 Apr.

Jun Li¹, Carl Armon², Frank J Palella³, Ellen Tedaldi⁴, Richard M Novak⁵, Jack Fuhrer⁶, Gina Simoncini⁴, Kimberly Carlson², Kate Buchacz¹, HIV Outpatient Study (HOPS) Investigators

Collaborators
HIV Outpatient Study (HOPS) Investigators:
Jun Li, Kate Buchacz, Marcus D Durham, Cheryl Akridge, Stacey Purinton, Nabil Rayeed, Selom Agbobil-Nuwoaty, Kalliope Chagaris, Kimberly Carlson, Carl Armon, Linda Battalora, Jonathan Mahnken, Frank J Palella, Saira Jahangir, Conor Daniel Flaherty, Patricia Bustamante, John Hammer, Kenneth S Greenberg, Barbara Widick, Rosa Franklin, Douglas J Ward, Troy Thomas, Cheryl Stewart, Jack Fuhrer, Linda Ording-Bauer, Rita Kelly, Jane Esteves, Ellen M Tedaldi, Ramona A Christian, Faye Ruley, Dania Beadle, Princess Davenport, Richard M Novak, Andrea Wendrow, Stockton Mayer, Mia Scott, Billie Thomas, Loraine Van Slyke, Cynthia Mayer, Terry Beitler, Karen Maroney, Denise Franklin

261.

Sustained and cumulative impact of an electronic medical record-based alert on a hepatitis C birth cohort screening program

J Viral Hepat. 2021 Apr 25. doi: 10.1111/jvh.13524. Online ahead of print.

Claus J Fimmel¹, Mohammad Q Khan¹, Yuliya Belopolsky¹, Polina Imas¹, Anuhya Gampa¹, Amnon Sonnenberg²

262.

Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian 'surveillance and treatment of prisoners with hepatitis C' project (SToP-C)

Harm Reduct J. 2021 Apr 26;18(1):46. doi: 10.1186/s12954-021-00494-4.

Jake Rance¹, Lise Lafferty², Carla Treloar², SToP-C Study Group

Collaborators

SToP-C Study Group:

Stuart Loveday, Gregory Dore, Andrew Lloyd, Jason Grebely, Tony Butler, Natasha Martin, Georgina Chambers, Carla Treloar, Marianne Byrne, Roy Donnelly, Colette McGrath, Julia Bowman, Lee Trevethan, Luke Grant, Terry Murrell, Nicky Bath, Mary Harrod, Alison Churchill, Kate Pinnock, Sallie Cairnduff

263.

Implementation of a Hepatitis C Treatment Program Into a Primary Care Residency Clinic

PRiMER. 2021 Jan 22;5:1. doi: 10.22454/PRiMER.2021.532368. eCollection 2021.

Morgan Adams Rhodes¹, Mark Humphrey¹

264.

Using the Electronic Health Record to Characterize the Hepatitis C Virus Care Cascade

Public Health Rep. 2021 Apr 8;333549211005812. doi: 10.1177/00333549211005812.Online ahead of print.

Shannon M Christy^1 2 3 4, Richard R Reich⁵, Julie A Rathwell^3 6, Susan T Vadaparampil^1 3 4, Kimberly A Isaacs-Soriano^3 6, Mark S Friedman^2 4, Richard G Roetzheim^1 3 7, Anna R Giuliano^3 4 6

265.

Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease

Nephrol Dial Transplant. 2021 Apr 12;gfab072. doi: 10.1093/ndt/gfab072. Online ahead of print.

Meghan E Sise¹, Thomas McQuaid², Paul Martin³

266.

Risk factors for loss to follow-up of persons who inject drugs enrolled at syringe services programs in Kentucky

Int J Drug Policy. 2021 Apr 10;95:103255. doi: 10.1016/j.drugpo.2021.103255.Online ahead of print.

Jaime Soria¹, Tisha Johnson², Jana Collins³, Greg Corby-Lee³, James Thacker³, Connie White², Ardis Hoven³, Alice Thornton³

267.

Atherosclerotic Cardiovascular Disease in Individuals with Hepatitis C Viral Infection

Curr Cardiol Rep. 2021 Apr 6;23(5):52. doi: 10.1007/s11886-021-01475-6.

Alison L Bailey¹, Saif Al-Adwan², Eliea Sneij³, Nicholas Campbell³, Matthew E Wiisanen⁴

268.

Predictors of hepatitis C treatment outcomes in a harm reduction-focused primary care program in New York City

Harm Reduct J. 2021 Mar 31;18(1):38. doi: 10.1186/s12954-021-00486-4.

Jacob Ziff¹, Trang Vu², Danielle Dvir², Farah Riazi², Wilma Toribio², Scott Oster², Keith Sigel², Jeffrey Weiss²

269.

Impact of antiviral therapy with Direct Acting Antiviral Agents (DAAs) on kidney disease in patients with chronic hepatitis C

Minerva Gastroenterol (Torino). 2021 Apr 1. doi: 10.23736/S2724-5985.21.02849-X.Online ahead of print.

Fabrizio Fabrizi¹, Roberta Cerutti², Carlo M Alfieri^2 3, Ezequiel Ridruejo^4 5

270.

Hepatitis E Infection in a Longitudinal Cohort of HCV and HCV/HIV Coinfected Persons

AIDS Res Hum Retroviruses. 2021 Apr 1. doi: 10.1089/AID.2020.0303. Online ahead of print.

Kenneth E Sherman^1 2, Shyam Kottilil³, Susan D Rouster⁴, Enass A Abdel-Hameed⁵, Ceejay L Boyce⁶, Heidi L Meeds⁷, Norah Terrault⁸, M Tarek Shata⁹

271.

Association of exercise participation levels with cardiometabolic health and quality of life in individuals with hepatitis C

BMJ Open Gastroenterol. 2021 Mar;8(1):e000591. doi: 10.1136/bmjgast-2020-000591.

Kate Hallsworth^1 2 3, Shion Gosrani¹, Sarah Hogg¹, Preya Patel¹, Aaron Wetten¹, Rachael Welton¹, Stuart McPherson^4 2, Matthew D Campbell^5 6

272.

High hepatitis C virus seropositivity, viremia, and associated risk factors among trans women living in San Francisco, California

PLoS One. 2021 Mar 30;16(3):e0249219. doi: 10.1371/journal.pone.0249219. eCollection 2021.

Christopher J Hernandez¹, Dillon Trujillo¹, Sofia Sicro¹, Joaquin Meza¹, Mackie Bella¹, Emperatriz Daza¹, Francisco Torres¹, Willi McFarland^1 2, Caitlin M Turner^1 2, Erin C Wilson^1 2

273.

The 2020 Nobel Prize for Medicine or Physiology for the Discovery of Hepatitis C Virus: A Triumph of Curiosity and Persistence

Hepatology. 2021 Mar 30. doi: 10.1002/hep.31830. Online ahead of print.

Marc G Ghany¹, Anna S F Lok², Jules L Dienstag³, Stephen M Feinstone¹, Jay H Hoofnagle⁴, T Jake Liang¹, Leonard B Seeff⁵, David E Cohen⁶, Jorge A Bezerra⁷, Raymond T Chung³

274.

Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in children with chronic hepatitis C virus: part 2 of the DORA study

Hepatology. 2021 Apr 2. doi: 10.1002/hep.31841. Online ahead of print.

Maureen M Jonas¹, Susan Rhee², Deirdre A Kelly³, Antonio Del Valle-Segarra⁴, Cornelia Feiterna-Sperling⁵, Susan Gilmour⁶, Regino P Gonzalez-Peralta⁷, Loreto Hierro⁸, Daniel H Leung⁹, Simon C Ling¹⁰, Yuri Lobzin¹¹, Steven Lobritto¹², Tatsuki Mizuochi¹³, Michael R Narkewicz¹⁴, Vishakha Sabharwal¹⁵, Jessica Wen¹⁶, Hoi Kei Lon², John Marcinak², Andrew Topp², Rakesh Tripathi², Etienne Sokal¹⁷

275.

Risks for acquiring hepatitis C virus among women in the United States

Public Health Nurs. 2021 Mar 22. doi: 10.1111/phn.12892. Online ahead of print.

Theresa Watts¹, Diane Lauver², Traci Snedden², Susan Zahner²

276.

Hepatitis C standards of care: A review of good practices since the advent of direct-acting antiviral therapy

Clin Res Hepatol Gastroenterol. 2021 Mar 15;45(2):101564.doi: 10.1016/j.clinre.2020.11.001. Online ahead of print.

Jeffrey V Lazarus¹, Camila A Picchio², Danielle Guy², Soo Aleman³, Cary James⁴, Felice A Nava⁵, Anne Øvrehus⁶, Juan Turnes⁷, John W Ward⁸, Andy Ustianowski⁹

277.

Risk Factors Associated With Chronic Liver Enzyme Elevation in Persons With HIV Without Hepatitis B or C Coinfection in the Combination Antiretroviral Therapy Era

Open Forum Infect Dis. 2021 Feb 24;8(3):ofab076. doi: 10.1093/ofid/ofab076.eCollection 2021 Mar.

Shannon Wood^1 2 3 4, Seung Hyun Won^3 5, Hsing-Chuan Hsieh^3 5, Tahaniyat Lalani^3 5 6, Karl Kronmann^3 6, Ryan C Maves^3 7, Gregory Utz^3 7, Christina Schofield^3 4, Rhonda E Colombo^3 5 4, Jason F Okulicz^3 8, Jason Blaylock^2 3, Brian K Agan^3 5, Anuradha Ganesan^2 3 5

278.

Non-Invasive Reliable Methods to Objectify the Positive Influence of Hepatitis C Virus Treatment on Liver Stiffness

Gastroenterology Res. 2021 Feb;14(1):31-40. doi: 10.14740/gr1347. Epub 2021 Feb 19.

Florian Bert¹, Jona Theodor Stahmeyer², Andra-Livia Parpalea¹, Siegbert Rossol¹

279.

The Changing Epidemiology of Hepatitis C Virus Infection in the United States During the Years 2010 to 2018

Am J Public Health. 2021 Mar 18;e1-e7. doi: 10.2105/AJPH.2020.306149. Online ahead of print.

Deborah Holtzman¹, Alice K Asher¹, Sarah Schillie¹

280.

Higher Levels of Fibrosis in a Cohort of Veterans with Chronic Viral Hepatitis are Associated with Extrahepatic Cancers

J Clin Exp Hepatol. Mar-Apr 2021;11(2):195-200. doi: 10.1016/j.jceh.2020.08.001.Epub 2020 Aug 9.

Ameer Abutaleb¹, Jose Antonio Almario², Saleh Alghsoon², Ji Ae Yoon³, Kate Gheysens², Shyam Kottilil⁴, Eleanor Wilson⁴

281.

Treatment failure with DAA therapy: importance of resistance

J Hepatol. 2021 Mar 11;S0168-8278(21)00169-0. doi: 10.1016/j.jhep.2021.03.004.Online ahead of print.

Christoph Sarrazin¹

282.

Social vulnerability in persons with chronic hepatitis C virus infection is associated with a higher risk of prescription opioid use

Sci Rep. 2021 Mar 15;11(1):5883. doi: 10.1038/s41598-021-85283-6.

Adeel A Butt^1 2 3 4, Peng Yan⁵, Shashi Kapadia⁶, Abdul-Badi Abou-Samra⁷, Naveed Z Janjua^8 9, Said Ibrahim⁶

283.

Impact of Behavioral Health Consultation on Hepatitis C Treatment Outcomes at a Federally Qualified Health Center; Philadelphia, PA

J Prim Prev. 2021 Apr;42(2):203-215. doi: 10.1007/s10935-021-00627-2. Epub 2021 Mar 18.

Kaitlin Grosgebauer¹, Tyler S Bartholomew^2 3, Katherine Huynh⁴, Travis Cos^4 5

284.

Constructing a middle-range theory to explain the uptake of hepatitis C tests in prison

Nurse Res. 2021 Mar 18. doi: 10.7748/nr.2021.e1782. Online ahead of print.

Kathryn Jack¹, Paul Linsley²

285.

Decreases in markers of monocyte/macrophage activation after hepatitis C eradication in HIV/HCV co-infected women

AIDS. 2021 Mar 11. doi: 10.1097/QAD.0000000000002869. Online ahead of print.

Audrey L French¹, Dara Grennan, Elizabeth Daubert, Eric C Seaberg, Marion Peters, Michael Augenbraun, Margaret Fischl, Seble Kassaye, Ricardo Franco, Mark Kuniholm, Adaora A Adimora, Kimberly Workowski, Kathleen M Weber

286.

Attitudes toward pharmacy-based HCV/HIV testing among people who use drugs in rural Kentucky

J Rural Health. 2021 Mar 5. doi: 10.1111/jrh.12564. Online ahead of print.

Michelle Duong¹, Chris Delcher², Patricia R Freeman², April M Young^3 4, Hannah L F Cooper⁵

287.

Systematic review: Accuracy of the enhanced liver fibrosis test for diagnosing advanced liver fibrosis and cirrhosis

J Gastroenterol Hepatol. 2021 Mar 5. doi: 10.1111/jgh.15482. Online ahead of print.

Chetanya Sharma¹, Sara Cococcia^1 2, Nicola Ellis¹, Julie Parkes³, William Rosenberg¹

288.

Exploring and understanding HCV patient journeys- HEPCARE Europe project

BMC Infect Dis. 2021 Mar 5;21(1):239. doi: 10.1186/s12879-021-05928-9.

Shannon Glaspy¹, Gordana Avramovic^1 2, Tina McHugh^1 2, Cristiana Oprea³, Julian Surey^4 5, Irina Ianache³, Juan Macías⁶, Alistair Story⁷, Walter Cullen¹, John S Lambert⁸

289.

Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry

Clin Infect Dis. 2021 Mar 2;ciaa1510. doi: 10.1093/cid/ciaa1510. Online ahead of print.

Fernanda Q Onofrio¹, Curtis Cooper², Sergio M Borgia³, Marie-Louise Vachon⁴, Alnoor Ramji⁵, Leslie B Lilly⁶, Alexander Wong⁷, Joshua Booth¹, Izza Sattar¹, Heidy Morales¹, Samuel Lee⁸, Brian Conway⁹, Jordan J Feld¹

290.

Where are the children in national hepatitis C policies? A global review of national strategic plans and guidelines

JHEP Rep. 2021 Jan 15;3(2):100227. doi: 10.1016/j.jhepr.2021.100227. eCollection 2021 Apr.

Farihah Malik¹, Heather Bailey², Polin Chan³, Intira Jeannie Collins⁴, Antons Mozalevskis⁵, Claire Thorne¹, Philippa Easterbrook⁶

291.

Lymphocyte Landscape after Chronic Hepatitis C Virus (HCV) Cure: The New Normal

Int J Mol Sci. 2020 Oct 10;21(20):7473. doi: 10.3390/ijms21207473.

Alip Ghosh¹, Sara Romani¹, Shyam Kottilil¹, Bhawna Poonia¹

292.

County-Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005-2017

Hepatology. 2021 Feb 20. doi: 10.1002/hep.31756. Online ahead of print.

Eric W Hall¹, Sarah Schillie², Adam S Vaughan³, Jeb Jones¹, Heather Bradley⁴, Ben Lopman¹, Eli Rosenberg⁵, Patrick Sullivan¹

293.

HCV virology and diagnosis

Clin Res Hepatol Gastroenterol. 2021 Feb 23;45(3):101626.doi: 10.1016/j.clinre.2021.101626. Online ahead of print.

Steven Roger¹, Alexandra Ducancelle¹, Hélène Le Guillou-Guillemette¹, Catherine Gaudy², Françoise Lunel³

294.

Willingness to Participate in Research among Black Patients with Liver Disease: A National Cross-Sectional Study

J Viral Hepat. 2021 Mar 4. doi: 10.1111/jvh.13493. Online ahead of print.

F Hunter McGuire^1 2, Kat André^2 3, Minyone L Bradsher², Dawn Harrison⁴, Richard K Sterling⁵, K Rajender Reddy⁶, Marina Serper⁶, Carol E Golin^1 7, Nancy Reau⁸, Joseph K Lim⁹, David R Nelson¹⁰, Souvik Sarkar¹¹, Donna M Evon^2 4

295.

High HCV cure rates among people who inject drugs and have suboptimal adherence: A patient-centered approach to HCV models of care

Int J Drug Policy. 2021 Mar 1;93:103135. doi: 10.1016/j.drugpo.2021.103135.Online ahead of print.

Brianna L Norton¹, Matthew J Akiyama², Julia H Arnsten³, Linda Agyemang⁴, Moonseong Heo⁵, Alain H Litwin⁶

296.

Hepatitis C treatment in a co-located mental health and alcohol and drug service using a nurse-led model of care

J Viral Hepat. 2021 Feb 17. doi: 10.1111/jvh.13487. Online ahead of print.

Brendan L Harney^1 2, Rebecca Brereton³, Bradley Whitton¹, Danusia Pietrzak³, Emma Paige¹, Stuart K Roberts^4 5, Susanne Birks³, Sudeep Saraf³, Margaret E Hellard^1 2, Joseph S Doyle^1 2

297.

Improvement of health-related quality of life and psychological well-being after HCV eradication with direct-acting antiviral agents. Real life setting data of an Italian cohort valued by Hepatitis Quality of Life Questionnaire (HQLQv2)

Health Psychol Res. 2021 Jan 20;8(3):9450. doi: 10.4081/hpr.2020.9450.eCollection 2020 Dec 30.

Gaetano Bertino¹, Rosalia Ragusa², Liberato Simone Corsaro³, Evelise Frazzetto¹, Vincenzo Messina⁴, Lucio Inguscio⁵, Carlo Lai⁵, Marilena Maglia⁶, Andrea Nunnari⁷, Pasquale Caponnetto⁶

298.

A Survey of Practices in the United States Regarding Hepatitis C Screening in Pregnant Women

Clin Ther. 2021 Feb 5;S0149-2918(21)00020-5. doi: 10.1016/j.clinthera.2021.01.016.Online ahead of print.

Elizabeth A Godar¹, Ravi Jhaveri²

299.

Initiation of Low-threshold Buprenorphine in Nontreatment Seeking Patients With Opioid Use Disorder Engaged in Hepatitis C Treatment

J Addict Med. 2021 Feb 5. doi: 10.1097/ADM.0000000000000807. Online ahead of print.

Kristi Hill¹, Laura Nussdorf, Julia D Mount, Rachel Silk, Chloe Gross, David Sternberg, Phyllis Bijole, Miriam Jones, Randy Kier, Dana Mccullough, Poonam Mathur, Shyam Kottilil, Henry Masur, Sarah Kattakuzhy, Elana S Rosenthal

300.

The persistence of underreporting of hepatitis C as an underlying or contributing cause of death, 2011-2017

Clin Infect Dis. 2021 Feb 9;ciab108. doi: 10.1093/cid/ciab108. Online ahead of print.

Philip R Spradling¹, Yuna Zhong¹, Anne C Moorman¹, Loralee B Rupp², Mei Lu², Eyasu H Teshale¹, Mark A Schmidt³, Yihe G Daida⁴, Joseph A Boscarino⁵, Stuart C Gordon^2 6

301.

Direct-Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C

Hepatol Commun. 2020 Nov 17;5(2):203-216. doi: 10.1002/hep4.1634. eCollection 2021 Feb.

Haesuk Park¹, Hyun Jin Song¹, Xinyi Jiang¹, Linda Henry¹, Robert L Cook², David R Nelson³

302.

The impact of electronic medical record system implementation on HCV screening and continuum of care: a systematic review

Ann Hepatol. 2021 Feb 4;24:100322. doi: 10.1016/j.aohep.2021.100322. Online ahead of print.

Lauren Barter¹, Curtis L Cooper²

303.

Screening for Sexually Transmitted Infections During Hepatitis C Treatment to Predict Reinfection Among People With HIV

Open Forum Infect Dis. 2020 Dec 30;8(2):ofaa643. doi: 10.1093/ofid/ofaa643.eCollection 2021 Feb.

Lucas A Hill¹, Natasha K Martin², Francesca J Torriani², Sonia Jain³, Huifang Qin⁴, Wm Christopher Mathews⁴, Edward R Cachay²

304.

The Impact of Hepatitis C and Liver Disease on Risk of Complications After Total Hip and Knee Arthroplasty: Analysis of Administrative Data From Louisiana and Texas

Arthroplast Today. 2021 Feb 2;7:200-207. doi: 10.1016/j.artd.2020.12.016. eCollection 2021 Feb.

Brett Salomon¹, Peter C Krause², Vinod Dasa², Lizheng Shi³, Deryk Jones⁴, Andrew G Chapple⁵

305.

Hepatitis C direct-acting antiviral outcomes in patients 75 years and older

JGH Open. 2020 Dec 18;5(2):253-257. doi: 10.1002/jgh3.12480. eCollection 2021 Feb.

Parmvir Parmar^1 2, Stephen D Shafran³, Sergio M Borgia⁴, Karen Doucette³, Curtis L Cooper^1 2

306.

Deinduction of P-glycoprotein resulting in delayed viral response during hepatitis C treatment

J Clin Pharm Ther. 2021 Feb 3. doi: 10.1111/jcpt.13374. Online ahead of print.

Jennifer E Stark¹, Jennifer L Cole¹

307.

Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study

Lancet Gastroenterol Hepatol. 2021 Mar;6(3):169-184. doi: 10.1016/S2468-1253(20)30359-9.Epub 2021 Jan 28.

Ellen Dugan¹, Sarah Blach¹, Mia Biondi², Zongzhen Cai¹, Mindi DePaola¹, Chris Estes¹, Jordan Feld³, Ivane Gamkrelidze¹, Shyamasundaran Kottilil⁴, Siya Ma¹, Poonam Mathur¹, Shauna Montoya¹, Devin Razavi-Shearer¹, Kathryn Razavi-Shearer¹, Sarah Robbins-Scott¹, Jonathan Schmelzer¹, Homie Razavi⁵

308.

Outcomes of Hepatitis C Virus Seropositive Donors to Hepatitis C Virus Seronegative Liver Recipients: A Large Single Center Analysis

Ann Hepatol. 2021 Jan 27;100318. doi: 10.1016/j.aohep.2021.100318. Online ahead of print.

Lindsay A Sobotka¹, Khalid Mumtaz¹, Michael R Wellner¹, Sean G Kelly¹, Lanla F Conteh¹, A James Hanje¹, Austin Schenk², Ashraf El-Hinnawi², Sylvester Black², Kenneth Washburn², Todd Pesavento³, Reem Daloul³, Anthony J Michaels⁴

309.

A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease

PLoS One. 2021 Feb 1;16(2):e0245962. doi: 10.1371/journal.pone.0245962. eCollection 2021.

Jeremy D Baker^1 2, Rikki L Uhrich², Gerald C Kraemer³, Jason E Love⁴, Brian C Kraemer^1 2 5 6

310.

Relationship between hepatitis C virus (HCV) IgG index values and quantitative HCV RNA results in HCV IgG-reactive serum samples

Diagn Microbiol Infect Dis. 2021 Jan 19;100(1):115311. doi: 10.1016/j.diagmicrobio.2021.115311.Online ahead of print.

Harry E Prince¹, Elizabeth M Marlowe², Dale S Schwab²

311.	Delays and Gaps in Progressing Through the Hepatitis C Virus Cascade of Care: An Underserved Safety-net Hospital Experience
	Chantal Gomes¹, Dina Ginzberg¹, Robert J Wong^2 3

312.

Mortality is Not Increased in SARS-CoV-2 Infected Persons With Hepatitis C Virus Infection

Liver Int. 2021 Feb 3. doi: 10.1111/liv.14804. Online ahead of print.

Adeel A Butt^1 2, Peng Yan¹, Rashid A Chotani^3 4, Obaid S Shaikh^1 5

313.

Applicability of a new specialty pharmacy-reported measure describing completion of therapy for hepatitis C

J Manag Care Spec Pharm. 2021 Feb;27(2):263-267. doi: 10.18553/jmcp.2021.27.2.263.

Clay Bolduc¹, Kenneth McCall 3rd², Kirsten Stickney³, Alycia Gelinas³, Eileen Levesque³

314.

Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree

J Manag Care Spec Pharm. 2021 Feb;27(2):137-146. doi: 10.18553/jmcp.2021.27.2.137.

Stephen C Ijioma¹, Vasco M Pontinha¹, David A Holdford¹, Norman V Carroll¹

315.

Hepatitis B Virus Reactivation in Cancer Patients Receiving Direct-Acting Antivirals for Hepatitis C Virus Infection

J Viral Hepat. 2021 Feb 1. doi: 10.1111/jvh.13478. Online ahead of print.

Haley Pritchard^1 2 3, Jessica P Hwang⁴, Georgios Angelidakis², Marcel Yibirin², Lan Wang⁵, Ethan Miller⁵, Harrys A Torres^2 5

316.

Pharmaceutical citizenship in an era of universal access to hepatitis C treatment: Situated potentials and limits

Health (London). 2021 Jan 28;1363459320988887. doi: 10.1177/1363459320988887.Online ahead of print.

Jake Rance¹, Tim Rhodes^1 2, Kari Lancaster¹

317.

Long-Term Patient Centered Outcomes in Cirrhotic Patients with Chronic Hepatitis C After Achieving Sustained Virologic Response

Clin Gastroenterol Hepatol. 2021 Jan 22;S1542-3565(21)00076-8.doi:10.1016/j.cgh.2021.01.026. Online ahead of print.

318.

Experiences of an HCV Patient engagement group: a seven-year journey

Res Involv Engagem. 2021 Jan 25;7(1):7. doi: 10.1186/s40900-021-00249-2.

UNC Chapel Hill HCV Patient Engagement Group; Scott Kixmiller¹, Anquenette P Sloan², Summer Wadsworth², Finton Brown², Lourdes Chaney³, Larry Houston², Kim Thomas⁴

319.

Hepatitis C Virus Transmission Clusters in Public Health and Correctional Settings, Wisconsin, USA, 2016-2017 1

Emerg Infect Dis. 2021 Feb;27(2):480-489. doi: 10.3201/eid2702.202957.

Karli R Hochstatter, Damien C Tully, Karen A Power, Ruth Koepke, Wajiha Z Akhtar, Audrey F Prieve, Thomas Whyte, David J Bean, David W Seal, Todd M Allen, Ryan P Westergaard

320.

Identifying the Hidden Population: Former Intravenous Drug Users Who Are No Longer in Contact with Services. "Ask a Friend"

Diagnostics (Basel). 2021 Jan 25;11(2):170. doi: 10.3390/diagnostics11020170.

Sarah R Donaldson^1 2, Andrew Radley^1 2, John F Dillon^1 3

321.

Assessment of health-related quality of life and health utilities in Australian patients with cirrhosis

JGH Open. 2020 Dec 10;5(1):133-142. doi: 10.1002/jgh3.12462. eCollection 2021 Jan.

Steven M McPhail^1 2, Samath Amarasena³, Katherine A Stuart⁴, Kelly Hayward⁵, Rohit Gupta⁶, David Brain^1 2, Gunter Hartel⁷, Tony Rahman⁶, Paul J Clark⁸, Christina M Bernardes⁶, Richard Skoien³, Benjamin Mckillen³, Andrew Lee⁸, Leshni Pillay⁹, Lei Lin⁶, Myat Myat Khaing⁶, Leigh Horsfall^4 5, Elizabeth E Powell^4 5, Patricia C Valery⁷

322.

Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington

Drug Alcohol Depend. 2021 Jan 11;220:108525. doi: 10.1016/j.drugalcdep.2021.108525.Online ahead of print.

Maria A Corcorran¹, Judith I Tsui², John D Scott³, Julia C Dombrowski⁴, Sara N Glick⁴

323.

Impact of a Nurse Care Coordinator Supporting a Clinical Pharmacist Practitioner in Further Managing HCV-Infected Patients

Gastroenterol Nurs. 2021 Jan 12. doi: 10.1097/SGA.0000000000000578. Online ahead of print.

Anita Yang¹, Debbie Zachary, Jane Giang

324.

Hepatitis C virus infection and polysubstance use among young adult people who inject drugs in a rural county of New Mexico

Drug Alcohol Depend. 2021 Jan 11;220:108527. doi: 10.1016/j.drugalcdep.2021.108527.Online ahead of print.

Katherine Wagner¹, Yuna Zhong², Eyasu Teshale², Kirsten White¹, Erin L Winstanley³, Jennifer Hettema⁴, Karla Thornton⁵, Birgitta Bisztray¹, Philip Fiuty⁶, Kimberly Page⁷

325.

Why do patients with chronic hepatitis C drink alcohol? An examination of pain, depression, and drinking motives

J Viral Hepat. 2021 Jan 21. doi: 10.1111/jvh.13474. Online ahead of print.

Julius M Wilder^1 2, Donna M Evon³, Rae Jean Proeschold-Bell^4 5, Jia Yao^4 5, Malik Muhammed Sohail⁴, Donna Niedzwiecki⁶, Christina Makarushka^4 5, Terra Hodge¹, Andrew J Muir^1 2

326.

HIV, HCV, and HBV incidence and residual risk in US blood donors before and after implementation of the 12-month deferral policy for men who have sex with men

Transfusion. 2021 Jan 18. doi: 10.1111/trf.16250. Online ahead of print.

Whitney R Steele¹, Roger Y Dodd¹, Edward P Notari¹, James Haynes¹, Steven A Anderson², Alan E Williams², Rita Reik³, Debra Kessler⁴, Brian Custer⁵, Susan L Stramer¹, Transfusion-Transmissible Infections Monitoring System (TTIMS)

327.

Liver Abnormalities after Elimination of HCV Infection: Persistent Epigenetic and Immunological Perturbations Post-Cure

Pathogens. 2021 Jan 7;10(1):E44. doi: 10.3390/pathogens10010044.

Stephen J Polyak^1 2 3, I Nicholas Crispe^1 4, Thomas F Baumert^5 6

328.

Hepatitis C Antiviral Treatment Decreases All-Cause Complications After Total Joint Arthroplasty Regardless of the Presence of Fibrosis

J Arthroplasty. 2021 Jan 8;S0883-5403(20)31285-7. doi: 10.1016/j.arth.2020.12.025.Online ahead of print.

Ella Cornell¹, David Novikov², Ruijia Niu², Kevin Staatz¹, Ran Schwarzkopf³, Eric L Smith⁴

329.

Adherence to Direct-Acting Antiviral Therapy in People Actively Using Drugs and Alcohol: The INCLUD Study

Open Forum Infect Dis. 2020 Nov 19;8(1):ofaa564. doi: 10.1093/ofid/ofaa564.eCollection 2021 Jan.

Kristina M Brooks¹, Jose R Castillo-Mancilla², Mary Morrow³, Samantha MaWhinney³, Sarah E Rowan^2 4, David Wyles^2 4, Joshua Blum⁴, Ryan Huntley¹, Lana M Salah¹, Arya Tehrani¹, Lane R Bushman¹, Peter L Anderson¹, Jennifer J Kiser¹

330.

Beyond a 'post-cure' world: Sketches for a new futurology of hepatitis C

Int J Drug Policy. 2021 Jan 13;103042. doi: 10.1016/j.drugpo.2020.103042. Online ahead of print.

Kate Seear¹, Suzanne Fraser², Adrian Farrugia³, Kylie Valentine⁴

331.

Incidence and Impact of Persistent Viremia on SVR Rates in Patients Receiving Direct-Acting Antiviral Therapy

Open Forum Infect Dis. 2020 Nov 26;7(12):ofaa569. doi: 10.1093/ofid/ofaa569.eCollection 2020 Dec.

Alicia B Carver¹, Autumn D Zuckerman¹, Joshua DeClercq², Leena Choi², Cody A Chastain³

332.

Patient-Reported Outcomes 12 Months After Hepatitis C Treatment with Direct-Acting Antivirals: Results from the PROP UP Study

Liver Int. 2021 Jan 2. doi: 10.1111/liv.14781. Online ahead of print.

Marina Serper¹, Donna M Evon², Jipcy Amador³, Paul W Stewart³, Souvik Sarkar⁴, Anna S Lok⁵, Richard K Sterling⁶, Bryce B Reeve⁷, Carol E Golin⁸, K Rajender Reddy¹, Joseph K Lim⁹, Nancy Reau¹⁰, David R Nelson¹¹, Adrian M Di Bisceglie¹², Michael W Fried²

333.

Progress towards hepatitis C virus elimination in high-income countries: an updated analysis

Liver Int. 2021 Jan 2. doi: 10.1111/liv.14779. Online ahead of print.

Ivane Gamkrelidze¹, Jean-Michel Pawlotsky², Jeffrey V Lazarus³, Jordan J Feld⁴, Stefan Zeuzem⁵, Yanjun Bao⁶, Ana Gabriela Pires Dos Santos⁶, Yuri Sanchez Gonzalez⁶, Homie Razavi¹

334.

Sex Differences in Extrahepatic Outcomes After Antiviral Treatment for Hepatitis C

Am J Gastroenterol. 2020 Dec 24;Publish Ahead of Print. doi: 10.14309/ajg.0000000000001095.Online ahead of print.

Jia Li¹, Stuart C Gordon, Yueren Zhou, Joseph A Boscarino, Mark A Schmidt, Yihe G Daida, Loralee B Rupp, Sheri Trudeau, Mei Lu, CHeCS Investigators

335.

Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond

Chem Rev. 2021 Jan 7. doi: 10.1021/acs.chemrev.0c00648. Online ahead of print.

Ashley N Matthew¹, Florian Leidner¹, Gordon J Lockbaum¹, Mina Henes¹, Jacqueto Zephyr¹, Shurong Hou¹, Desaboini Nageswara Rao¹, Jennifer Timm¹, Linah N Rusere¹, Debra A Ragland¹, Janet L Paulsen¹, Kristina Prachanronarong¹, Djade I Soumana¹, Ellen A Nalivaika¹, Nese Kurt Yilmaz¹, Akbar Ali¹, Celia A Schiffer¹

336.

HPTN 078: High Prevalence of HCV Antibodies Among Urban U.S. Men Who Have Sex with Men (MSM) Independent of HIV Status

Clin Infect Dis. 2020 Dec 21;ciaa1869.doi: 10.1093/cid/ciaa1869. Online ahead of print.

Risha Irvin¹, Theresa Gamble², Jowanna Malone¹, Zhe Wang³, Ethan Wilson³, James P Hughes⁴, Jason Farley¹, Kenneth H Mayer⁵, Carlos Del Rio⁶, D Scott Batey⁷, Vanessa Cummings¹, Robert H Remien⁸, Chris Beyrer¹, Chloe L Thio¹

337.

Novel Hepatitic C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic

J Infect Dis. 2020 Nov 27;222(Supplement_9):S758-S772. doi: 10.1093/infdis/jiaa366.

Sahar Bajis¹, Tanya L Applegate¹, Jason Grebely¹, Gail V Matthews¹, Gregory J Dore¹

338.

We Must Do Better: Addressing HCV Treatment Barriers in Persons Who Inject Drugs in the United States

J Infect Dis. 2020 Nov 27;222(Supplement_9):S773-S781. doi: 10.1093/infdis/jiaa574.

Stacey B Trooskin^1 2, Gregory Dore³, Jay Kostman¹

339.

Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis

Lancet Gastroenterol Hepatol. 2021 Jan;6(1):39-56. doi: 10.1016/S2468-1253(20)30303-4.Epub 2020 Nov 18.

Fengyi Jin¹, Gregory J Dore², Gail Matthews², Niklas Luhmann³, Virginia Macdonald³, Sahar Bajis², Rachel Baggaley³, Bradley Mathers³, Annette Verster³, Andrew E Grulich²

340.

Direct-Acting Antivirals and Organ Transplantation: Is There Anything We Can

J Infect Dis. 2020 Nov 27;222(Supplement_9):S794-S801. doi: 10.1093/infdis/jiaa420.

Matthew R Kappus^1 2, Cameron R Wolfe^1 2, Andrew J Muir^1 2

341.

Nontargeted Hepatitis C Screening in an Urban Emergency Department in New York City

J Emerg Med. 2020 Nov 16;S0736-4679(20)30970-7. doi: 10.1016/j.jemermed.2020.09.034.Online ahead of print.

Ethan A Cowan¹, Amreen Dinani², Samantha Brandspiegel¹, Clare O'Brien-Lambert¹, Joseph Zaheer¹, Erick Eiting¹, George Loo¹, Yvette Calderon¹

342.

Hepatitis C Seroprevalence Among Consecutive Labor and Delivery Admissions in Two New York City Hospitals

Open Forum Infect Dis. 2020 Oct 23;7(11):ofaa514. doi: 10.1093/ofid/ofaa514.eCollection 2020 Nov.

Tatyana Kushner^1 2, Claire Park², Dana Masand², Brian Wagner³, Marie Grace⁴, Emma Rosenbluth^1 2, Clara Rodriquez-Rivas^1 2, Hernis de la Cruz⁵, Jessica Overbey⁵, Rhoda Sperling^2 6

343.

Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

J Hepatol. 2020 Nov 18;S0168-8278(20)33770-3. doi: 10.1016/j.jhep.2020.11.017.Online ahead of print.

Julia Dietz¹, Velia Chiara Di Maio², Adolfo de Salazar³, Dolores Merino⁴, Johannes Vermehren¹, Stefania Paolucci⁵, Andreas E Kremer⁶, Magdalena Lara⁷, Maria Rodriguez Pardo⁸, Heinz Zoller⁹, Elisabetta Degasperi¹⁰, Kai-Henrik Peiffer¹, Laura Sighinolfi¹¹, Francisco Téllez¹², Christiana Graf¹, Valeria Ghisetti¹³, Jonas Schreiber¹⁴, Elisa Fernández-Fuertes¹⁵, Lucio Boglione¹⁶, Leopoldo Muñoz-Medina¹⁷, Rudolf Stauber¹⁸, William Gennari¹⁹, Blanca Figueruela²⁰, Jesús Santos²¹, Pietro Lampertico¹⁰, Stefan Zeuzem¹, Francesca Ceccherini-Silberstein², Federico García³, Christoph Sarrazin²²

344.

Changing Urban-Rural Disparities in the Utilization of Direct-Acting Antiviral Agents for Hepatitis C in U.S. Medicare Patients, 2014-2017

Am J Prev Med. 2020 Nov 18;S0749-3797(20)30435-9. doi: 10.1016/j.amepre.2020.08.031.Online ahead of print.

Ping Du¹, Xi Wang², Lan Kong², Thomas Riley 3rd³, Jeah Jung⁴

345.

Reasons for Not Seeking Hepatitis C Treatment among People Who Inject Drugs

Subst Use Misuse. 2020 Nov 18;1-10. doi: 10.1080/10826084.2020.1846198.Online ahead of print.

Leith Morris¹, Linda Selvey¹, Owain Williams¹, Charles Gilks¹, Andrew Smirnov^1 2

346.

Factors associated with hepatitis C and HIV testing uptake among men who inject image and performance enhancing drugs

Drug Alcohol Rev. 2020 Nov 8. doi: 10.1111/dar.13198. Online ahead of print.

Vivian D Hope¹, James McVeigh², Emma Begley¹, Rachel Glass³, Claire Edmundson³, Ellen Heinsbroek³, Joseph Kean⁴, John Campbell⁵, Mark Whitfield¹, Gareth Morgan⁶, Dean Acreman⁷, Josie Smith⁷

347.

Exploring patient willingness to accept hepatitis C-infected kidneys for transplantation

BMC Nephrol. 2020 Nov 10;21(1):473. doi: 10.1186/s12882-020-02114-y.

Gretchen C Edwards¹, Maren E Shipe², Lindsay Smith³, Christianna Gamble³, David Shaffer⁴, Beatrice P Concepcion⁵, Rachel Forbes⁴

348.

Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy

Gastrointest Tumors. 2020 Oct;7(4):134-143. doi: 10.1159/000510341. Epub 2020 Sep 14.

Nicholas Lim¹, Dupinder Singh¹, Scott Jackson², John R Lake¹

349.

Routine Screening and Linkage to Care for Hepatitis C Virus in an Urban Safety-Net Health System, 2017-2019

Public Health Rep. 2020 Nov 11;33354920969179. doi: 10.1177/0033354920969179.Online ahead of print.

Bijou R Hunt¹, Christopher Ahmed¹, Kimberly Ramirez-Mercado¹, Christopher Patron¹, Nancy R Glick^1 2

350.

Multicenter, Double-Blind, Randomized Trial of Emricasan in Hepatitis C Treated Liver Transplant Recipients with Residual Fibrosis or Cirrhosis

Liver Transpl. 2020 Nov 8. doi: 10.1002/lt.25934. Online ahead of print.

Ethan W Weinberg¹, Michael P Curry², Catherine T Frenette³, Fredric G Regenstein⁴, Eugene R Schiff⁵, Zachary D Goodman⁶, James Mac Robinson⁷, Jean L Chan⁷, Joanne C Imperial⁷, K Rajender Reddy¹

351.

Direct-acting antiviral Hepatitis C treatment cascade and barriers to treatment initiation among US men and women with and without HIV

J Infect Dis. 2020 Nov 3;jiaa686. doi: 10.1093/infdis/jiaa686. Online ahead of print.

Danielle F Haley¹, Andrew Edmonds², Catalina Ramirez³, Audrey L French⁴, Phyllis Tien⁵, Chloe L Thio⁶, Mallory D Witt⁷, Eric C Seaberg⁸, Michael W Plankey⁹, Mardge H Cohen¹⁰, Adaora A Adimora¹¹

352.

Estimating the Year Each State in the United States Will Achieve the World Health Organization

Adv Ther. 2020 Nov 3;1-18. doi: 10.1007/s12325-020-01535-3. Online ahead of print.

Mark Sulkowski¹, Wei-Han Cheng², Steven Marx², Yuri Sanchez Gonzalez², John Strezewski², Nancy Reau³

353.

The hepatitis C virus care cascade in the New York City jail system during the direct acting antiviral treatment era, 2014-2017

EClinicalMedicine. 2020 Oct 5;27:100567. doi: 10.1016/j.eclinm.2020.100567.eCollection 2020 Oct.

Justin Chan¹, Fatos Kaba¹, Jessie Schwartz², Angelica Bocour², Matthew J Akiyama³, Zachary Rosner¹, Ann Winters², Patricia Yang¹, Ross MacDonald¹

354.

PERCEPTIONS OF NETWORK BASED RECRUITMENT FOR HEPATITIS C TESTING AND TREATMENT AMONG PERSONS WHO INJECT DRUGS: A QUALITATIVE EXPLORATION

Int J Drug Policy. 2020 Nov 4;88:103019. doi: 10.1016/j.drugpo.2020.103019.Online ahead of print.

Kathleen M Ward¹, Sean D McCormick², Mark Sulkowski³, Carl Latkin⁴, Geetanjali Chander⁵, Oluwaseun Falade-Nwulia⁶

355.

A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis C

BMC Infect Dis. 2020 Oct 29;20(1):802. doi: 10.1186/s12879-020-05531-4.

Jessica Ramsay¹, Julie Marsh¹, Alisa Pedrana^2 3, Nada Andric⁴, Richard Norman⁵, Wendy Cheng^6 7 8, Steve Webb^3 9, Nikolajs Zeps¹⁰, Matthew Bellgard¹¹, Todd Graves¹², Margaret Hellard^{2 3 13 14 15}, Tom Snelling^{16 17 18 19 20}

356.

Early Outcomes of Multivisceral Transplant using Hepatitis C Positive Donors

Ann Thorac Surg. 2020 Oct 26;S0003-4975(20)31736-7. doi: 10.1016/j.athoracsur.2020.08.044.Online ahead of print.

William G McMaster Jr¹, Zakiur M Rahaman², Maren E Shipe³, Eric N Quintana⁴, Emily M Sandhaus⁵, Sarah S Smith⁶, Jerod E Crockett⁷, Rachel C Forbes⁸, Kelly H Schlendorf⁹, Ashish S Shah¹⁰

357.

Low Adherence Achieves High HCV Cure Rates Among People Who Inject Drugs Treated With Direct-Acting Antiviral Agents

Open Forum Infect Dis. 2020 Aug 26;7(10):ofaa377. doi: 10.1093/ofid/ofaa377.eCollection 2020 Oct.

Brianna L Norton¹, Matthew J Akiyama¹, Linda Agyemang¹, Moonseong Heo², Irene- Pericot-Valverde³, Alain H Litwin^3 4 5

358.

Immune system control of hepatitis C virus infection

Curr Opin Virol. 2020 Oct 30;46:36-44. doi: 10.1016/j.coviro.2020.10.002.Online ahead of print.

Johnasha D Stuart¹, Eduardo Salinas¹, Arash Grakoui²

359.

Outcomes of Hepatitis C Virus Treatment in the New York City Jail Population: Successes and Challenges Facing Scale up of Care

Open Forum Infect Dis. 2020 Jun 30;7(7):ofaa263. doi: 10.1093/ofid/ofaa263.eCollection 2020 Jul.

Justin Chan¹, Jessie Schwartz², Fatos Kaba¹, Angelica Bocour², Matthew J Akiyama^1 3, Laura Hobstetter¹, Zachary Rosner¹, Ann Winters², Patricia Yang¹, Ross MacDonald¹

360.

The use of organs from hepatitis C virus-viremic donors into uninfected recipients

Curr Opin Organ Transplant. 2020 Dec;25(6):620-625. doi: 10.1097/MOT.0000000000000826.

Jeffrey A Kahn¹

Triple E for HCV: Treatment Expansion in High-Risk Communities: Engagement, Education and Eradication of HCV